CA2057387A1 - Recombinant bovine herpesvirus type 1 polypeptides and vaccines - Google Patents

Abstract

29310-20005.20 Client ID None PATENT

ABSTRACT OF THE DISCLOSURE
Recombinant subunit vaccines against bovine herpesvirus type 1 (BHV-1) are provided, as well as methods of vaccination and methods of recombinantly producing the subunit antigens employed in the vaccines.
The subunit antigens employed include recombinant BHV-1 gI, BHV-1 gIII, BHV-1 gIV, antigenic fragments of BHV-1 gI, gIII and gIV, or combinations of the above.

RBNS06F2.WP . 01

Description

29310-20005.20 Client ID None PATENT

POLYPEPTID~S AND VACCINES

Cross Reference to Related Application This application is a continuation-in-part of U.S. patent application Ser. No. 07/219,939, filed 15 July 1988, which is incorporated herein by reference in its entirety and from which priority is claimed pursuant to 35 USC 120.

Technical Field The present invention relates generally to the prevention of disease in cattle. MorP particularly, the instant invention is directed to the recombinant production of bovine herpesvirus type 1 antigens for use in subunit vaccines to protect cattle against bovine herpesvirus type 1 infection.

Background ;~
Bovine herpesvirus type 1 (BHV-1) is an economically significant pathogen of cattle. BHV-1, which is also known as infectious bovine rhinotracheitis virus, causes severe respiratory infections, conjunctivitis, vulvovaginitis, abortions, encephalitis, and generalized systemic infections. If an animal recovers from a primary infection, the virus remains in the host in a latent state. Reactivation of the virus can be provoked by certain endogenous or exogenous physical modifications in the animal, or experimentally by treatment of the animal with glucocorticoids like dexamethasone.

RBNS06F0.WP .12 . .

-29310-20005.20 Client ID None PATENT

In an effort to control BHV-1 infections, killed virus and attenuated live-virus vaccines have been developed. While these vaccines appear to induce some level of protection in cattle, the level of immunity is well below that necessary to afford complete or near-complete protection. For example, the vaccines do not always prevent the establishment of a latent infection by a virulent field strain of BHV-1.
Furthermore, the safety of the l:ive-virus vaccines has been questioned. It has been shown recently that two live BHV-1 vaccine strains can be reactivated by the use of dexamethasone, indicating that at least some BHV-1 vaccines can themselves establish a latent infection.
See, e.g., Gerber et al. (1978) Am. J. Vet. Res.
39:753-760; Jericho et al. (1983) Can. J. Com. Med.
47:133-139; Pastoret et al. (1980) Infect. Immun.
29:483-488. Subunit vaccines, i.e. vaccines including select proteins separated from the whole virus, afford a method for overcoming the problems inherent in the use of live and attenuated virus vaccines.
Several polypeptides of BHV-1 have now been studied. Misra et al. (1981) J. Virol. 40:367-378, reports on the partial characterization of a number of BHV-1 polypeptides and their immunoprecipitation with antiserum. van Drunen Littel-van den Hurk et al. (1984) Virology 135:466-479 and van Drunen Littel-van den Hurk et al. (1985) Virology 144:216-227 are directed to monoclonal antibodies developed against BHV-1 glycoproteins, and the ability of the monoclonal antibodies to neutralize virus and participate in antibody-dependent complement-mediated lysis in vitro.
See also Collins et al. (1984) J. Virol. 52:403-409;
Okazaki et al. (1986) Virology 150:260-264. van Drunen Littel-van den Hurk et al. (1985) Virology 144:204-215 is directed to the purification of BHV-1 glycoproteins by RBNS06FO . WP .12 , ~ , - . , .
: : : ,, `: '.; ' 29310-20005.20 Client ID None PATENT

immunoadsorbent chromatography and the production of antiserum in rabbits. van Drunen Littel-van den Hurk et al. (1986) J. Clin. Microbiol. 23:274-282 is directed to in vitro immunoreactivity of purified BHV-1 glycoproteins and bovine antiserum. Okazaki et al. (1987) Arch. Virol.
92:17-26 pertains to in vitro studies of the reactivities of monoclonal antibodies against ~3HV-1 glycoproteins with infected cells. Babiuk et al. (:L987) Virology 159:57 66 relates to the purification of gI, gIII and gIV from virus infected cell lysates. This reference also discloses that gI of BHV-1 corresponds to gB of herpes simplex virus (HSV); gIII corresponds to gC; and gIV
corresponds to gD. Purified gI, gIII and gIV have been shown to induce high levels of neutralizing antibody in cattle and participate in antibody dependent cell cytotoxicity of BHV-1 cells. The purified glycoproteins were also shown to protect cattle from disease. Babiuk et al. (1987) Virology 159:57-66. van Drunen Littel-van den Hurk et al. (1990) Vaccine 8:358-368 confirmed the protectivity of gI, gIII and gIV and studied the epitope specificity of the immune response to the glycoprotein vaccines. Hughes et al. (1988) ~rch. Virol. 103:47-60 identified three neutralizing antigenic domains on gIV.
None of the above art, however, discloses the recombinant production of BHV-1 glycoproteins for use in recombinant vaccines. Mayfield et al. (1983) J. Virol.
47:259-264 discloses the cloning of a BHV-1 strain and a restriction map. Fitzpatrick et al. (1989) Virology 173:46-57, describe the nucleotide sequence of gIII.
Pachl et al. (1987) J. Virol. 61:315-325 describe the recombinant expression of a glycoprotein from the human pathogen HSV-1. There was no demonstration, however, that the recomhinant polypeptide from the human virus was, in fact, protective in a human host. See also PCT

RBNS06FO . WP .12 .

29310-20005.20 Client ID None PATENT

Pub. No. W088/02634; U.S. Patent Nos. 4,661,349;
4,642,333.
Fitzpatrick et al. (19~8) J. Virol.
62:4239-4248 describe the expression of gI and gIII in murine LMTK- cells. The transfected cells were shown to stimulate the production of neutralizing antibodies in mice. Fitzpatrick et al. (1990) describe the expression of deleted, truncated and hybrid forms of gI and gIII in murine LMTK-cells and epitope mapping of the same. Tikoo 10 et al. (1990) J. Virol. 64:5132-5142 disclose the mapping, cloning and sequencing of BHV-1 gIV, as well as the expression of gIV in bovine cells. van Drunen Littel-van den Hurk et al. (1989) J. ~irol. 63:2159-2168 disclose the expression of gI and gIII in a vaccinia virus vector. The recombinant vectors elicited a neutralizing antibody response in cattle immunized with the same. van Drunen ~ittel-van den Hurk et al. (Jan.
1991) J. Virol. 65:263-271 describe the expression of gI~J
by recombinant baculovirus. This disclosure was based in part on the present invention. Cattle immunized with recombinant gIV raised neutralizing antibodies thereto.

Disclosure of the Invention It has been discovered that recombinant subunit vaccines, based on selected BHV-1 glycoproteins, will protect cattle from disease. These vaccines are particularly useful in protecting cattle from shipping fever, complex syndrome which often includes infection by BHV-1. Surprising, these subunit vaccines are substantially more protective than prior art killed virus and attenuated live-virus vaccines. The recombinant subunit vaccines do not suppress the immunological response to other components often found in multivalent shipping fever vaccines. Further, the recombinant subunit vaccines of the present invention also eliminate RBNS06FO . WP .12 , '~. ' , : ,; ,;. : . :, , ,: . . ` : :,, ~: -29310-20005.20 Client ID None PATENT

the risk of infection from the live-virus vaccines. It has also been discovered that recombinant BHV-1 polypeptides maintain the proper epitopes necessary to protect immunized animals from d:isease. Both nonglycosylated polypeptides, and polypeptides glycosylated by heterologous host organisms, effectively elicit antibodies that neutralize virus infectivity and induce complement-mediated cell :Lysis. Based on these discoveries, the present invention can take several embodiments.
In one embodiment, the present invention is directed to a vaccine composition comprising a pharmaceutically acceptable vehicle and at least one recombinant subunit antigen. The recombinant subunit antigen comprises one or more neutralizing epitopes of a bovine herpesvirus type 1 (BHV-1) glycoprotein. The glycoprotein selected from the group consisting of BHV-1 gI, BHV-1 gIII and BHV-1 gIV.
In other embodiments, the subject invention is directed to nucleotide sequences encoding proteins substantially homologous and functionally equivalent to BHV-1 gI, BHV-1 gIII, BHV-1 gIV, or immunogenic fragments thereof.
In yet other embodiments the subject invention is directed to DNA constructs comprising an expression cassette comprised of:
(a) a DNA coding sequence for a polypeptide containing at least one neutralizing epitope of a BHV-~glycoprotein. The glycoprotein is selected from the group consisting of gI, gIII and gIV; and (b) control sequences that are operably linked to the coding sequence whereby the coding sequence can be transcribed and translated in a host cell, and at least one of the control sequences is he~erologous to the coding sequence.

RBNSO 6FO . WP . 12 ~ . `

'~

29310-20005.20 Client ID None PATENT

In another embodiment, the present invention is directed to host cells stably transformed by the above DNA constructs.
In still another embodiment, the subject invention is directed to methods of producing recombinant polypeptides comprising:
(a) providing a population of the above host cells; and (b) growing the population of cells under conditions whereby the polypeptide encoded by the expression cassette is expressed.
In another embodiment, the instant invention is directed to methods of treating or preventing BHV-1 infection in a bovine host comprising administering to the bovine host a therapeutically effective amount of a vaccine compositions described above.
These and other embodiments of the present invention will readily be apparent to those of skill in the art from the following disclosure.
Brief Description of the Figures Figure 1 shows the serum neutralizing antibody responses of animals immunized with BHV-1 glycoproteins.
Animals were immunized with various glycoproteins and boosted three weeks later. Titers were determined by a 50~ end point using 100 PFU of BHV-1 virus. The various glycoproteins are indicated as follows: gI (solid diamond), gIII (solid circle), gIV (solid square), gI/gIII (open diamond), gI/gIV (open square), gIII/gIV
(solid triangle), gI/gIII/gIV (open circle), commercial killed vaccine (open triangle), and placebo (-). See Example I.B.1.
Figure 2 shows the ADCC titers of sera obtained from calves immunized with BHV-1 glycoproteins or a com-mercial vaccine. The bars in the graph show the data for RBNS06FO . WP . lZ

`., , , " : , :' , . ' . ' ~ , .

, ' : ~ ~ :, .' . ~ , `

29310-20005.20 Client ID None PATENT

the various immunogens left to right as follows: gIII
(open), gIV (cross-hatched), gI/gIII (small dots), gI/gIV
(diagonal lines), gIII/gIV (large dots), gI/gIII/gIV
(waves), and a commercial vaccine (solid) See Example I.B.l.
Figure 3 shows the effect of immunization with BHV-l glycoproteins on clinical ]-esponse of calves to BHV-l/P. haemolytica challenge. T3 represents a commercial vaccine. Numbers above the bars indicate the total number of sick days (a clinical score of ten or more on any specific observation) animals in each group exhibited over a ten-day observation period. See Example I . B . 2.
Figure 4 shows the genomic location of BHV-l's major glycoprotein genes. The position and direction of transcription for the gIII, gI and gIV genes are shown by the arrows above the genomic map. ~indIII sites are marked by vertical lines, and the size in kilobase pairs i9 shown below the genomic map. The scale below the map measures genomic equivalents. Numbers next to gene designations show their position in genomic equivalents.
See Example II.B.l.
Figure 5 shows the nucleotide sequence and deduced amino acid sequence from a viral clone of the gI
gene. This gene encodes the gIa/gIb/gIc complex. The gIa precursor is cleaved into two peptides, gIb and gIc, which are linked by disulfide bonds to produce mature gIa. The gIb peptide is 438 amino acids long and encoded at the N-terminus of the gI gene. The gIc peptide is 428 amino acids long and encoded at the C-terminus of the gI
gene. Right-angle arrows show the start of the gIb and gIc peptides, and putative transmembrane sequences are underlined. See Example II.B.l.
Figure 6 is the nucleotide sequence and deduced amino acid seq~lence from a viral clone of gIII. The gene RBNSO 6FO . WP .12 29310-20005.20 Client ID None PATENT

encodes a 521 amino acid peptide. Putative transmembrane sequences are underlined. See Example II.B.1.
Figure 7 is the nucleotide sequence and deduced amino acid sequence from a viral clone of gIV. The gene encodes a peptide 417 amino acids long. The right-angle arrow marks the position of the Mature gIV sequence.
Putative transmembrane sequences are underlined.
Figure 8 shows the vaccinia transfer vector pgB
vax.
Figure 9 shows the construction of recombinant plasmid pgC vax. See Example II.
Figure 10 depicts the vaccinina transfer vector pgC vax.
Figure 11 shows the construction of the vaccinia expression vector p W-l.
Figure 12 depicts the construction of the vaccinia expression vector pW SL-1.
Figure 13 depicts the vaccinia expression vector p W-1/gIV with the full length gIV gene cloned into the BglII cloning site of pVVSL-1.
Figure 14 shows the vaccinia expression vector p W -l/gIVt which includes a modified BHV-1 gIV gene inserted into the BglII cloning site of p WSL-1.
Figure 15 shows the restriction maps for various SV40 expression vectors. 15A shows the restriction map for pRSVgI; 15B for pSV2gI; 15C for pRSVgIII; and 15D for pSV2gIII. The origins of the DNA
sequences are represented as follows: pBR322 (open boxes), Rous sarcoma virus (vertically hatched boxes), SV40 virus (diagonally hatched boxes), BHV 1 (solid boxes) and Tn5 (stippled boxes). The start and stop codons of gI and gIII are arrowed in the direction of transcription from the Rous sarcoma and SV40 virus pr~moters. Restriction endonuclease cleavage sites are indicated by letters: E = EcoRI, B = BglII, B/Ba =

RBNS06FO . WP .12 .

, -, ` ,.: ~ ': ' ;~ '.'; ''' ~ :`

29310-20005.20 Client ID None PATENT
g BglII-BamHI sites destroyed by ligation. See Example III.
Figure 16 shows the immune response of calves to partially purified recombinant gIV in Emulsigen P~US
or Avridine, affinity-purified authentic gIV in Avridine, commercially available killed BHV-1 vaccine, and placebo containing AcNPV-infected SF9 cells. The bars in the graph show the data for the various immunogens left to right as follows: recombinant gIV from baculovirus in Emulsigen PLUS ~solid); recombinant gIV from baculovirus in Avridine (small circles); gIV from BHV-1 in Avridine (small diagonal lines); commercial killed vaccine (large circles); placebo (large diagonal lines). See Example IV. All animals were immunized twice with 100 ~g of gIV.
(16A) ELISA titers were determined against affinity-purified gIV o~ BHV-1 and expressed as the reciprocal of the highest dilution resulting in an optical density at 450 nm of 0.1. (16B) Serum neutralizing antibody titers were expressed as a 50~ endpoint by using 100 PFU of BHV-1. (16C) Competition binding assays of bovine sera withmonoclonal antibodies 136 to 3D9S directed at epitopes I
to IV on glycoprotein gIV. Each percentage of specific competition represents the geometric mean for the eight animals in each group. Competitor antibody was used at a 1:10 dilution, which resulted in maximum competition levels.
Figure 17 shows various BHV-1 genomic library clones.
Figure 18 depicts the E. coli expression plasmid pgpll complete, carrying the entire gIb coding sequence plus DNA encoding the first eight amino aci.ds of gIc. See Example V.
Figure 19 shows the E. coli expression plasmid pBHC150~, carrying a deletion mutant of the BHV-1 gIII
gene. See Example V.

RB~S06FO . WP .12 :: , . ;
.

., `
' 29310-20005.20 Client ID None PATENT

Figure 20 shows the cloning strategy and the construction of pBHDsib. See Example V.
Figure 21 depicts the E~. coli expression plasmid pBHDsib, containing a gIV gene encoding the mature protein. See Example V.
Figure 22 depicts the adenovirus transfer vector, pAdBM5. * indicates the gene insertion site.
See Example VI.
Figure 23 shows the adenovirus vector, pAdBM5.gIV, which includes the gene coding for full-length gIV. See Example VI.
Figure 24 shows the serum antibody responses in animals immunized with gIV. The bars in the graphs show the data for the various immunogens left to right as follows: gIV from BHV-1 (solid), baculovirus (small diagonal lines), adenovirus (large diagonal lines), vaccinia virus (small dots), and E. coli (large dots), or placebo (circles). A. gIV-specific ELISA titers, expressed as the reciprocal of the highest dilution resulting in a reading of two standard deviations above the control value. B. Serum neutralizing antibody titers, expressed as a 50~ endpoint using 100 p.f.u. of BHV-1. Error bars show the standard deviation of the mean of eight animals.
Figure 25 shows the anti-gIV isotype profiles of animals immunized with gIV from BHV-1 (+), baculovirus (~), adenovirus (O),vaccinia virus (+) and E. coli (~
or placebo (~). The IgG1 (A), IgG2 (~) and IgM (C) titers were determined in an indirect ELISA with gIV-coated plates and expressed as the reciprocal of the highest dilution resulting in a reading of two standard deviations above the control. Each value represents the geometric mean of eight animals.
Figure 26 shows the competition binding of sera from immunized calves with monoclonal antibodies 136 to RBNS06FO . WP .12 .

: , ' : :
. ~ ' ' ., 293:L0-20005.20 Client ID None PATENT

3D9S, specific for epitopes I to IV on glycoprotein gIV.
Animals were immunized with gIV from BHV-1 (solid), baculovirus (circles), adenovirus (small diagonal lines), vaccinia virus (cross-hatch), or E. coli (large diagonal lines), or placebo (clear). Each percentage of specific competition represents the geometric mean for the eight animals in each group. Competitor antibody waa used at a dilution of 1:10, which results in optimal competition levels.
Figure 27 shows the effect of immunization with gIV on clinical disease in animals challenged with BHV-1.
Temperature responses (A) and clinical scores (B) of animals immunized with gIV from BHV-1 (~), baculovirus (O),adenovirus (~), vaccinia virus (~) and E. coli (~), or placebo (+) are shown as the geometric mean for the eight animals in each group.
Figure 28 shows the effect of immunization with gIV on weight change in animals challenged with BHV-1.
Weight loss is shown as the geom~tric mean for the eight animals in each group.
Figure 29 shows the effect of immunization with gIV on the extent of viral replication and mucosal immunity in animals challenged with BHV-1. Figure 29A
depicts the results of an experiment wherein virus titers were determined in the nasal secretions from animals immunized on the challenge day and on alternate days after challange with gIV from BHV-1 (+), baculovirus (O), adenovirus (-), vaccinia virus (v) and E. coli (~), or placebo (~). Figure 29B shows an experiment wherein neutralizing and total antibody responses were determined in the nasal secretions from animals vaccinated on the challenge day with gIV from BHV-1, baculovirus (Bac.), adenovirus (Adeno), vaccinia virug (Vac.), or E. coli (B). Error bars show the standard deviation of the mean of eight animals.

RBNS06FO . WP .12 `
.
.
:'`

. :. ' :: ' : :.

29310-20005.20 Client ID None PATE,NT

Detailed Description The practice of the present invention will employ, unless otherwise indicated, conventional virology, microbiology, molecular biology and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Maniatis et al., Molecular Cloning:_ A Laboratory Manual (1982); DNA Cloning: A
Practical Approach, vol. I & II (D. Glover, ed.);
Oligonucleotide Synthesis (N. Gait, ed., 1984); Nucleic Acid Hybridization (B. Hames & S. Higgins, eds., 1985);
Transcription and Translation (B. Hames & S. Higgins, eds., 1984); Animal Cell Culture (R. Freshney, ed., 1986); Perbal, A Practical Guide to Molecular Cloninq (1984).
All patents, patent applica~ions and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

A. Definitions The following terminology will be used in ac-cordance with the definitions set out below in describing the present invention.
A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.
A "vector" is a replicon, such as a plasmid, phage, or cosmid, to which another DNA segment may be at-tached so as to bring about the replication of the at-tached segment.
A l'double-stranded DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, R~S06FO .WP .12 :
.

..

293:L0-20005.20 Client ID None PATENT

thymine, or cytosine) in its normal, double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA).
A DNA "coding sequence" is a DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, procaryotic sequences, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A
polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.
A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence i9 bound at the 3' terminus by the translation start codon (ATG) of a coding sequence and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a RBNS06FO . WP .12 ., , :, , 29310-20005.20 Client ID None PATENT

transcription initiation site (conveniently defined by mapping with nuclease Sl), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eucaryotic promoters will often, but now always, contain "TATA" boxes and "CAT" boxes.
Procaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.
DNA "control sequences" refers collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the transcription and translation of a coding sequence in a host cell.
A coding sequence is ~operably linked to" or "under the control of" control sequences in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.
A "host cell" is a cell which has been transformed, or is capable of transformation, by an exogenous DNA sequence.
A cell has been "transformed~' by exogenous DNA
when such exogenous DNA has been introduced inside the cell membrane. Exogenous DNA may or may not be integrated (covalently linked) to chromosomal DNA making up the genome of the cell. In procaryotes and yeasts, for example, the exogenous DNA may be maintained on an episomal element, such as a plasmid. With respect to eucaryotic cells, a stably transformed cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eucaryotic cell to RBNS06FO . WP .12 '' , ', ,~

293:L0-20005.20 Client ID None PATENT

establish cell lines or clones comprised of a population of daughter cells containing the exogenous DNA.
A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.
Two DNA or polypeptide sequences are "substantially homologous" when at least about 85~
(preferably at least about 90~, and most preferably at least about 95~) of the nucleotides or amino acids match over a defined length of the molecule. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., supra; DNA Cloning, vols I & II, supra; Nucleic Acid Hybridization, supra.
The term "functionally equivalent" intends that the amino acid sequence of the sub~ect protein is one that will elicit an immunological response, as defined below, equivalent to the specified BHV-l immunogenic polypeptide.
A "heterologous'l region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature. Thus, when the heterologous region encodes a viral gene, the gene will usually be flanked by DNA that does not flank the viral gene in the genome of the source virus or virus-infected cells. Another example of the heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Allelic variation or naturally occurring mutational events do not RBNS06FO . WP .12 .

: . !... : . : .

293:L0-20005.20 Client ID None PATENT

give rise to a heterologous region of DNA, as used herein.
A composition containing molecule A is "sub-stantially free of" molecule B when at least about 75~ by weight of the total of A + B in the composition is molecule A. Preferably, molecule A comprises at least about 90~ by weight of the total of A + B in the composi-tion, more preferably at least about 99~ by weight.
"Bovine host~ refers to cattle of any breed for which it may be desirable to immunize against BHV-1 infection, whether or not the bovine host is already infected or latently infected by BHV-1. A bovine host can be of any age. Thus, the term encompasses calves as well as adult cattle.
The term "polypeptide" is used in its broadest sense, i.e., any polymer of amino acids ~dipeptide or greater) linked through peptide bonds. Thus, the term "polypeptide" includes proteins, oligopeptides, protein fragments, analogs, muteins, fusion proteins and the like. A ~glycoprotein~ is a glycosylated polypeptide.
"Native" proteins or polypeptides refer to proteins or polypeptides recovered from BHV-1 virus or BHV-1-infected cells. Thus, the term "native BHV-1 polypeptide" would include naturally occurring BHV-1 proteins and fragments thereof. ~Non-native"
polypeptides refer to polypeptides that have been produced by recomhinant DNA methods or by direct synthesis. "Recombinant~ polypeptides refer to polypeptides produced by recombinant DNA technic~ues;
i.e., produced from cells transformed by an exogenous DNA
construct encocling the desired polypeptide.
An "antigen" refers to a molecule containing one or more epitopes that will stimulate a host's immune system to make a humoral and/or cellular antigen-specific RBNS06FO . WP .12 `

29310-20005.20 Client ID None PATENT

response. The term is also used interchangeably with "immunogen."
By "subunit antigen" is meant an antigen entity separate and discrete from a whole virus (live or killed). Thus, an antigen contained in a cell free extract would constitute a "subunit antigen" as would a substantially purified antigen.
A "hapten" is a molecule containing one or more epitopes that does not stimulate a host~s immune system to make a humoral or cellular response unless linked to a carrier.
The term "epitope" refers to the site on an antigen or hapten to which a specific antibody molecule binds. The term is also used interchangeably with "antigenic determinant~ or "antigenic determinant site."
An "immunological response" to a composition or vaccine is the development in the host of a cellular and/
or antibody-mediated immune response to the composition or vaccine of interest. Usually, such a response consists of the subject producing antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T
cells directed specifically to an antigen or antigens included in the composition or vaccine of interest.
The terms "immunogenic polypeptide" and "immunogenic amino acid sequence" refer to a polypeptide or amino acid sequence, respectively, which elicit antibodies that neutralize viral infectivity, and/or mediate antibody-complement or antibody dependent cell cytotoxicity to provide protection of an immunized hostO
An "immunogenic polypeptide~ as used herein, includes the full length (or near full length) sequence of the desired BHV-1 glycoprotein or an immunogenic fragment thereof. By "immunogenic fragment" is meant a fragment of a polypeptide which includes one or more epitopes and thus elicits antibodies that neutralize viral infectivity, RBNSO 6FO . WP .12 : ~: ' ~ ' '. : ' : '.
.' : . : ~ :
-:

29310-20005.20 Client ID None PATENT

and/or mediates antibody-complement or antibody dependent cell cytotoxicity to provide protection of an immunized host. Such fragments will usually be at least about 5 amino acids in length, and preferably at least about 10 to 15 amino acids in length. There is no critical upper limit to the length of the fragment, which could comprise nearly the full length o~ the protein sequence, or even a fusion protein comprising fragments of two or more of the BHV-1 subunit antigens.
The term "treatment" as used herein refers to either (i) the prevention of infection or reinfection (prophylaxis), or (ii) the reduction or elimination of symptoms of BHV-l (therapy).

B. General Methods Bovine herpesvirus type 1, or ~HV-1, is a well-~nown and well-characterized virus, of which many strains are known. See, e.g., Gibbs et al. (1977) Vet.
Bull. (London) 47:317-343. BHV-1, also known as infectious bovine rhinotracheitis virus, is similar in structure to other herpesviruses, and possesses a linear double-stranded DNA genome of approximately 140 kilobase pairs. BHV-1 can remain latent in infected animals, probably in trigeminal or sacral ganglia, and, as discussed above, can be reactivated with relative ease.
The BHV-~ genome specifies more than 25 structural polypeptides, of which about 11 are believed to be glycosylated. Of particular interest to the present invention are the glycoproteins gI (previously referred to as GVP 6/lla/16, which comprises gIb and gIc), gIII (previously referred to as GVP 9 or its dimer, GVP 3), and gIV (previously referred to as GVP llb).
Glycoprotein gI is a complex of three glycoproteins with apparent molecular weights of approximately 130 k (gIa), 74 k (gIb), and 55 k (gIc). gIa is the precursor of gIb RBNS06FO . WP .12 :

29310-20005.20 Client ID None PATENT

and gIc. Glycoprotein gIII has an apparent molecular weight of about 91 k and also occurs as a dimer with an approximate apparent molecular weight of 180 k.
Glycoprotein gIV has an apparent molecular weight of ap-proximately 71 k, and also occurs as an approximate 140 kdimer.
The BHV-1 gene for gI maps between 0.422 and 0.443 genome equivalents (Figure 4) in the HindIII A
fragment described by Mayfield et al. (1983), supra. The gIII gene maps between 0.120 and 0.131 genome equivalents (Figure 4) in the HindIII I fragment. Id. The gIV gene maps between 0.892 and 0.902 genome equivalents in the HindIII K fragment. The nucleotide sequences of the gI, gIII, and gIV genes are shown in Figures 5, 6, and 7, respectively.
A key aspect of the present invention is the provision of a recombinant subunit antigen useful in the production of BHV-1 vaccines. The subunit antigens of the present invention are polypeptides from at least one of the ~HV-1 glycoproteins gI, gIII, or gIV. In general, the polypeptide subunit antigens will usually be at least about 5 amino acids in length in order to encode an epitope, and preferably at least about 10-15 amino acids in length. There is no critical upper limit to the length of the subunit antigen, which could comprise the entire viral glycoprotein sequence, or even a fusion protein comprising the sequences of two or more of the viral glycoproteins.
The subunit antigens of the present invention are recombinant polypeptides. These recombinant subunits can take the form of partial glycoprotein sequences, full-length viral protein sequences, or even fusion proteins (e.g., with an appropriate leader for the recombinant host, or with another subunit antigen sequence for B~-1 or another pathogen). The subunit RBNS06FO . WP .12 .

- " :~
:: ` .: ` ~ : ., , : : :
: .
' ' ' ' , ~' ~ ' , ' ' ', ' .; ' ,' ' ' ' ' `

29310-20005.20 Client ID None PATENT

antigen, even though carrying epitopes derived from glycoproteins, does not require cJlycosylation.
While it is preferred to use subunit glycoproteins containing the ful].-length (or near full-length) sequence of the selected BHV-1 glycoprotein, shorter sequences encoding one or more epitopes can also be employed. The truncated sequence need only encode a "polypeptide neutralizing epitope"; i.e., an epitope which elicits antibodies that neutralize virus infectivity, and/or mediates antibody-complement or antibody dependent cell cyto~oxicity to provide protec-tion of an immunized host. See, e.g., ~abiuk et al.
(1975) Infect. Immun. 12:958-963; Babiuk et al. (1987), supra. Particularly preferred epitopes for screening the subunit antigens will be those epitopes that are exposed on the cell membrane of infected host cells, as well as those epitopes encompassing the attachment site on intact virions. Such epitopes can be defined by monoclonal antibody analysis. See, e.g., van Drunen Littel-van den Hurk et al. (1985) Virology 144:216-227; Okazaki et al.
(1987), supra. ~;
In the vaccines of the present invention, it will sometimes be preferable to have more than one polypeptide neutralizing epitope in the subunit antigen(s). Purthermore, it may also be desirable to include polypeptide neutralizing epitopes from more than one glycoprotein in ~he subunit antigen(s). In its simplest form, this can be achieved by employing a polypeptide encoding the complete sequence of a glycoprotein (usually encompassing more than one neutral-izing epitope), or by employing a combination of polypeptides encoding the sequences of two or all three of the viral glycoproteins. In a preferred embodiment employing native BHV-1 proteins, the subunit antigens would comprise, for example, gIV, a combination of gIV

RBNSO 6FO . WP .12 .. . ....
'; ~ ' ' ~ ' , ~ :

29310-20005.20 Client ID None PATENT

and gI (gIV/gI), a combination of gIV and gIII
(gIV/gIII), or a combination of gI and gIII (gI/gIII), or a combination of all three glycoproteins (gI/gIII/gIV).
When employing synthetic or recombinant polypeptides, the subunit antigen can be a single polypeptide encoding several neutralizing epitopes from just one of the viral glycoproteins, or several neutralizing epitopes from more than one of the viral glycoproteins (e.g., a fusion protein). Synthetic and recombinant subunit antigens can also comprise two or more discrete polypeptides encoding different neutralizing epitopes.
The subunit antigens of the present invention, particularly when they comprise short oligopeptides, may be conjugated to a vaccine carrier. Such carriers are well known in the art, such as bovine serum albumin (BSA), human serum albumin (HSA) and keyhole limpet hemocyanin (KLH). A particularly preferred carrier protein, rotavirus VP6, is disclosed in U.S. patent No.
5,071,651, the disclosure of which is hereby incorporated by reference it its entirety. The BHV-1 neutralizing epitopes of the present invention may also be incorporated within particle-forming viral polypeptides as a fusion protein, as described in U.S. Patent No.
4,722,840 and EPO Pub. No. 174,759. Alternatively, the BHV-l subunit antigens of the present invention can be incorporated into a foreign virus (e.g., vaccinia or adenovirus) as is known in the art and described more fully below in the examples.
The subunit antigen(s) are formulated into a vaccine composition comprising a pharmaceutically accept-able vehicle and, optionally, an adjuvant. Such formula-tions are well within the skill of the art. In general, the formulations will be particularly adapted for intra-muscular injection, since intravenous injection is usually not practical for large-scale application to RBNS06FO . WP .12 ' ~' ~

29310-20005.20 Client ID None PATEMT

domestic animals. Alternatively, the vaccines are given orally or intranasally, and the subunits formulated with a suitable oral carrier. It may be preferred to administer the vaccines of the present invention orally to raise mucosal immunity, as well as intramuscularly for systemic immunity. A pharmaceutically acceptable vehicle, suitable for parenteral injection, is usually nontoxic and nontherapeutic. Examples of such vehicles are water, saline, Ringer~s solution, dextrose solution, and Hank's solution. Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. Parenteral vehicles may also take the form of suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran.
The vehicle will also usually contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and tris buffer, while examples of preservatives include thimerosal, m- or o-cresol, formalin and benzyl alcohol. Standard formula-tions will either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a nonliquid formulation, the vehicle may comprise dextrose, human serum albumin, preservatives, etc., to which sterile water or saline could be added prior to administration.
Various adjuvants are known in the art which can also be employed in the vaccine formulations of the present invention; e.g., Freund's adjuvant, Avridine, 30 aluminum salts [Al(OH)3, AlPO4, A12(SO4)8], Ca3(PO4)2, saponin, DDA, Plusonics, oil-in-water emulsions (contain-ing, e.g., Avridine, dextran sulphate, Emulsigen PLUS or vitamin E) and water-in-oil emulsions (containing, e.g., polysorbate 80). The selection of the appropriate RB~S06FO . WP .12 ~ ' `
`:

~.
:

29310-20005.20 Client ID None PATENT

adjuvant and its concentration in the vaccine composition is within the skill of the art.
Many protocols for administering the vaccine composition of the present invention to animals are within the skill of the art. The preferred route of administration is parenteral, particularly intramuscular.
The concentration of the subunit antigen(s) in the vaccine composition i9 selected so that an effective dose is presented in the bovine host to elicit antibodies to the polypeptide neutralizing epitopes. Within wide limits, the dosage is not believed to be critical.
Typically, the vaccine composition is administered in a manner which will deliver between about 1 to about 1,000 ~g of the subunit antigen in a convenient volume of vehicle (e.g., about 1-10 ml). Preferably, the dosage in a single immunization will deliver from about 1 to about 500 ~g of subunit antigen, more preferably about 5-10 ~g to about 100-200 ~g (e.g., 10-100 ~g). It may also be preferred, although optional, to administer a second, booster immunization to the animal several weeks to several months after the initial immunization. To insure sustained high levels of protection against disease, it may be helpful to readminister a booster immunization to the animals on a periodic basis.
The subunit antigen can be produced from protein recovered from virus or virus-infected cells, or cells expressing the recombinant glycoproteins. For example, purified virus or virus-infected cells can be disrupted or lysed and subjected to immunoadsorbent chromatography to purify gI, gIII or gIV. See, e.g., van Drunen Littel-van den Hurk et al. (1985) Virology 144:204-215. The production of monoclonal antibodies is within the skill of the art. See, e.g., van Drunen Littel-van den Hurk et al. (1984), supra; Okazaki et al.
(1987), supra. Briefly, a mammal, such as a mouse, is RBNS06FO . WP .12 ' .

29310-20005.20 Client ID None PATENT

immunized with either purified virus or the purified viral glycoprotein of interest (e.g., SDS-PAGE purified) and antibody-producing B lymphocytes recovered.
Typically, these B lymphocytes are then fused with a continuous cell line to produce an immortal antibody-producing cell line; i.e., a hybridoma, trioma, etc. Immortal, antibody-producing cell lines can also be created by techniques other than fusion, such as direct transformation of B-lymphocytes with oncogen:ic DNA, or trans~ection with Epstein-Barr virus. See, e.g., M.
Schreier et al. (1980) Hybridoma Techniques; Hammerling et al. (1981) Monoclonal Antibodies and T-Cell Hybridomas; Kennett et al. (1980) ~onoclonal Antibodies;
see also U.S. Patent Nos. 4,341,761; 4,399,121;
4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500;
4,491,632; 4,493,890. Native BHV-l proteins which are immunopurified can be used in their entirety as subunit antigens, or fragments of the entire proteins containing the neutralizing epitopes can be employed as subunit antigens.
Non-native BHV-l polypeptides can be produced by a number of methods. For example, oligopeptides containing neutralizing epitopes can be prepared synthetically by known techniques. See, e.g., U.S.
Pa~ent No. 4,735,896. It is preferred, however, to prepare the non-native polypeptide subunit antigens by recombinant DNA methods.
Recombinant polypeptide subunit antigens are produced according to the present invention by construct-ing an expression cassette and trans~orming a host cell therewith to provide a cell line or culture capable of expressing the subunit antigen which is encoded within the expression cassette. The first step in constructing the expression cassette is to obtain a coding sequence for the glycoprotein or glycoprotein epitopes of RBNS06FO .WP .12 :

, - ~ , , ' .: . ' , '~

: .

29310-20005.20 Client ID None PATE'NT

interest. Coding sequences for gI, gIII and gIV are shown in Figures 5, 6 and 7. Thus, coding sequences can either be prepared directly by synthetic methods based on the disclosed sequence (or equivalent sequences encoding the same amino acids), or by using the disclosed sequence to design oligonucleotide probes to clone coding sequence using known techniques. See, e.g., Mayfield et al.
(1983), supra. The coding sequence can be comprised entirely of BHV-1 glycoprotein-encoding sequences, or such glycoprotein sequences can be fused to other sequences (e.g., leader sequences) so that a fusion protein is encoded. See, e.g., U.S. Patent Nos.
4,431,739; ~,425,437; 4,338,397. Synthetic coding sequences will also allow for the convenient construction of coding sequences which express BHV-1 glycoprotein analogs or "muteins". Alternatively, coding ~equences for muteins can be prepared by site-directed mutagenesis of native BHV-1 nucleotide gequences. The techniques of site-directed mutagenesis are known in the art.
Once an appropriate coding sequence for the subunit antigen has been prepared or isolated, it can be cloned into any suitable vector or replicon. Numerous cloning vectors or replicong are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. Examples of recombinant DNA vectors for cloning and host cells which can be transformed include various bacteriophage lambda vectors (E. coli), pBR322 (E. coll), pACYC171 (E. coli), pKT230 (gram-negative bacteria), pGV1106 (gram-negative bacteria), pLAFR1 (gram-negative bacteria), pME290 (non-E. coli gram-negative bacteria), pHV14 (E. coli and Bacillis subtilis), pBD9 (Bacillis), pIJ61 (Streptomyces), pUC6 (Streptomyces), actinophage dC31 (Streptomyces), YIp5 (Saccharomyces), YCpl9 (Saccharomyces), 2-micron plasmid (Saccharomyce9), and RB~S06FO.WP .12 .
: .
: ~, :-:, :. -: '.

29310-20005.20 Client ID None PATENT

bovine papilloma virus (mammalian cells). See, generally, DNA Cloninq, vols I & II, supra; Maniatis et al., supra; Perbal, supra.
To complete construction of expression cas-settes, the coding sequence as described above for thesubunit antigens is then operably linked to control sequences (e.g., a promoter, etc.), so that the DNA
sequence encoding the subunit antigen is transcribed into messenger RNA in the host cell transformed by the expres-sion cassette. It is within the skill of the art tooperably link the subunit antigen coding sequence to appropriate control sequences in order to bring about transcription and translation. In general, the coding sequence will be downstream from the promoter sequence and any expression regulatory regions, such as enhancers or operator sequence. If the subunit antigen coding sequence is linked to a heterologous coding sequence or start codon, then it is important to place the subunit antigen coding sequence in reading frame with the latter.
If the intended expression hogt is procaryotic, then it will also be necessary to include a ribosome binding site among the upstream control sequences. Downstream operably linked control sequences will usually comprise a transcription termination sequence, and a polyadenylation signal (for mammalian expression hosts).
When the intended expression host is a procaryotic or yeast cell, the promoter and other control sequences will necessarily be heterologous to the subunit antigen coding sequence. If the selected expression host cell is a mammalian cell, the control sequences can be homologous BHV-1 sequences, or preferably heterologous mammalian control sequences. The expression cassette can be constructed, for example, as a discrete molecular entity flanked by convenient restriction sites, or it can be constructed by inserting the coding sequence into a RB~S06FO .WP .12 ... . .
.

- ~ ., - .
: ' -,, ; ;-.. ~ ,:~ , ' :: :

29310-20005.20 Client ID None PATENT

previously constructed expression vector with an appropriate insertion site.
A number of procaryotic expression vectors are known in the art. See, e.g., U.S. Patent Nos. 4/~40,859i 4,436,815; 4,431,740; 4,431,739; 4,428,941; 4,425,437;
4,418,149; 4,411,994; 4,366,246; 4,342,832; see also U.K.
Publication Nos. GB2,121,054; G~2,008,123; GB2,007,675;
and European Publication No. 103,395. The preferred procaryotic expression vectors are those for E. coli.
Other preferred expression vectors are those for use in eucaryotic systems. Yeast expression vectors are also known in the art. See, e.g., U.S. Patent Nos. 4,446,235;
4,443,539; 4,430,428; see also European Publication Nos.
103,409; 100,561; 96,491.
One of the preferred expression hosts of the present invention are mammalian cells. Various cell lines and expression vectors are known in the art.
Examples of appropriate mammalian expression hosts include kidney cell lines (e.g., CV-l monkey kidney cell lines), fibroblast cell lines (e.g., human, murine or chicken embryo fibroblast cell lines), Chinese hamster ovary (CHO) cells, HeLa cells, mouse NI~/3T3 and/or LMTK
cells. It is also known to express heterologous proteins in myeloma cell lines employing immunoglobulin promoters.
25 See, e.g, Banerjee et al. (1983) Cell 33:729-740; U.S.
Patent No. 4,663,281. The selection of a mammalian cell line is not critical, and is within the skill o~ the art.
Various mammalian expression vectors employing viral promoters (e.g., SV40 early region promoter, Rous sarcoma virus, LTR promoter, etc.) are also well known in the art. See, e.g., Pachl et al. (1987), supra; Gorman et al. (1982) Proc. Natl. Acad. Sci. USA 79:6777-6781;
Southern et al. (1982) ~. Mol. App. Genet. 1:327-341; PCT
Publication No. W087/02062. Pre~erred eucaryotic expression vectors are those employing the vaccinia RB~SO 6FO . WP .12 . ,.: ~,: ` :`

- ` ~ : ,- .'. `. ;` ` `:

- : , . . . '.: ' 29310-20005.20 Client ID None PATENT

virus, the SV40 virus, or the Rous sarcoma virus, which are also well known in the art. See, e.g., Mackett et al. (1984) J. Virol. 49:857; DNA Cloning, vol. II, pp.
191-211, supra; PCT Publication No. W086/07593;
5 Chakrabarty et al. (1985) Mol. Cell. Biol. 5:3403.
Another preferred embocliment of the present invention is the expression of recombinant BHV-1 polypeptides in insect cells using viral vectors, such as baculovirus. For example, high levels of expression have been achieved with vectors based on Autographa californica nuclear polyhedrosis virus (AcNPV) in Spodoptera frugiperda cells. See, e.g., Smith et al.
(1983) J. Virol. 46:584-593; U.S. Pat. App. Serial No.
07/092,120, supra; Canadian Pat. App. Serial No. 545,803, supra.
Generally, a host cell which has been stably transformed by an expression cassette for the subunit antigen is selected to produce the recombinant polypeptide. A stably transformed host is one wherein the expression cassette has integrated into the host cell's chromosome. In the case of bacteria or yeast expression hosts, it may be preferred to select expression hosts which maintain the cassette on a non-integrating episomal element, such as a plasmid. The subunit antigen is produced by growing host cells transformed by the expression cassette under conditions which cause the expression of biologically active subunit antigen polypeptide. The appropriate conditions to bring about expression are well known in the art, and will depend primarily on the expression system and host selected. The subunit antigen polypeptide may be isolated from the host cells and purified. If the expression system secretes the subunit antigen, then the polypeptide can be purified directly from the growth media. If subunit antigen is not secreted, however, it RBNSO 6FO . WP . 12 `
- ~ . .

.

, :

293:L0-20005.20 Client ID None PATENT

may be necessary to disrupt the host cells and purify the subunit antigen polypeptide from the cellular lysate.
Various purification techniques, such as ~PLC and immunoaffinity chromatography, are known, and the selection of the appropriate purification and recovery method is within the skill of the art.
Described below are examples o~ the present invention which are provided only for illustrative purposes. The examples are not intended to limit the scope of the present invention in any way, as numerous embodiments within the scope of the claims will be appar-ent to those of ordinary skill in the art in light of the present disclosure. Those of ordinary skill in the art are presumed to be familiar with (or to have ready access to) the reference~ cited in the application, and the dis-closures thereof are incorporated b~ reference herein.

C. Experimental EXAMPLES

I

This example demonstrates the protection of cattle immunized with subunit vaccines made from purified BHV-l glycoproteins.

I.A. Materials and Methods I.A.1. Virus and Bacteria Strains P8-2 and 108 of BHV-1 were propagated in Georgia bovine kidney cells as described previously.
Babiuk et al. (1975) Infect. Immun. 12:958 963. For virus challenge of animals strain 108 was used, whereas for glycoprotein isolation the Cooper strain was used.

RBNS06FO .WP .12 .. . ............ .

; .; , 29310-20005.20 Client ID None PATENT

A culture of Pasteurella haemolytica (biotype A, serotype 1) was prepared as described previously.
Bielefeldt Ohmann et al. (1985) J. Infect. Dis.
151:937 947. In each case, the bacterial challenge was in the log phase of growth and had a titer of 1 to 2 x CFU/ml.

I.A.2. Monoclonal Antibodies and Immunoadsorbent Purification Monoclonal antibodies against gI, gIII, and gIV
were produced as described previously. van Drunen Littel-van den Hurk et al. (1984), supra. Clones lE11-lF6, lD6-G11 and lG6-2D9 which recognize gI, gIII, and gIV, respectively, were selected to prepare immunoadsorbent columns.
Purification of IgG fractions of monoclonal antibodies was carried out using protein A-Sepharose CL-4B (Pharmacia Montreal, Quebec). L'Italien in Method of Protein Microcharacterization, pp. 279-314 (J.E.
Shively ed. 1986). Monoclonal IgG was eluted from the protein A-Sepharose column with 50 mM triethylamine and was dialyzed thoroughly against 0.1 M HEPES, pH 7.5 (coupling bufferO CB). The purified IgG was linked to activated Affigel-10 (Bio-Rad Laboratories, Mississaugo, Ontario) at 5 mg protein/ml gel, according to the manufacturer's instructions.
Glycoproteins gI, gIII, and gIV were purified from virus-infected cell lysate as previously described.
van Drunen Littel-van den Hurk et al. (1985) Virology 144:216-227. Twenty-four hours postinfection, at a m.o.i. of 1, cultures were harvested and centrifuged at 1000 rpm to obtain infected cell pellets. Cells were resuspended in 1~ Nonidet-P40 (NP-40) and 1~ sodium deoxycholate (DOC) in 0.10 M Tris-hydrochloride, 0.15 M

RBNSO 6FO . WP .12 , .
-, " ' , -29310-20005.20 Client ID None PATENT

NaCl, (pH 7.5) and used as starting material for purification.
Immunoadsorbent columns with specificities for gI, gIII, and gIV, respectively, were prepared. After passage of the sample over the column in sample applica-tion buffer, the column was exchanged with 1 vol of fresh sample application buffer prior to washing with 2 vol of wash buffer [100 mM Tris, 500 mM NaCl, 1~ NP-40 (pH
7.5)]. The wash buffer was displaced from the column with 2 vol of water prior to elution of the specifically bound antigen with 50 mM triethylamine. The eluted fractions were monitored by removing 5-50 ~l collected fraction and performing a nonquantitative Bradford assay.
Those fractions that contained protein were then directly concentrated for further analysis. The column was reequilibrated in sample application buffer for reuse or stored in sample application buffer plus 0.02~
thimerosal. Columns prepared, used, and stored in this way have retained significant activity for almost a year.
I.A.3. Immunization and Pathogen Challenqe Purified glycoproteins were formulated with Avridine (N,N-dioctadecyl-N,N-bis) (2-hydroxylethylpropanediamine) as follows: 150 mg of Avridine was dissolved in 1 ml of absolute EtOH and then combined with 90 ~1 Tween 30 by thorough mixing. Next, 4.7 ml of Intralipid were combined with Avridine/EtOH and thoroughly mixed by vortexing. 4.0 mls of biological buffer, e.g. Hanks' buffered salt solution or PBS were added to the solution to complete the adjuvant preparation. The vaccine was prepared by mixing equal volumes of antigen and adjuvant solutions such that each animal received a dose of 100 ~g of glycoprotein + 15 mg of Avridine in a 2 ml volume.

~B~S06FO .WP .12 .

. . " ' : -. , . ~ :

:., 29310-20005.20 Client ID None PATENT

Groups of five animals each were immunized intramuscularly with the above preparations. Twenty-one days later animals were boosted and then challenged 3 weeks after booster immunization. Control unvaccinated calves were immunized with Avridine (adjuvant alone). A
further control group was immunized with a commercial killed virus vaccine (Triangle 3, Fort Dodge Laboratories, Iowa) as recommended by the manufacturer.
Blood samples were taken from animals at 10-day intervals for assessment of antibody responses.
Following immunization, animals were transported into an isolation pen and examined clinically, and rectal temperatures were recorded and blood samples were collected for various immunological assays to establish baseline immunological activity. The calve~ were then individually exposed to an aerosol of BHV-1, followed 4 days later with P. haemolytica. In each case, the aerosol was generated by a DeVilbiss Nebulizer, Model 65 (DeVilbiss, Barry, Ontario, Canada).
Treatment was for 4 min in the case of the virus and 5 min with P. haemolytica as described previously.
Bielefeldt Ohmann et al. (1985), supra.

I.A.4. SDS-PAGE. Western Blot, ELISA and ADCC
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) was carried out in 7.5~ dis-continuous slab gels under reducing conditions, as described previously. van Drunen Littel-van den Hurk et al. (1984), supra; Laemmli (1970) Nature (London) 30 227:680-685.
The Western blotting technique was performed as described previously. van Drunen Littel-van den Hurk et al. (1984), supra. After electrophoresis, virus lysates were electrophoretically transferred to nitrocellulose sheets. Subsequently, the instructions for use of the RBNS06FO .WP .12 . . ` " '`:

. . .
., , . . ' .
.`
.. - ` ~ .
- ' :
` : :,. .
,, , ~ :, ';`',, :

29310-20005.20 Client ID None PATENT

~3io-Rad (Mississaugo, Ontario) immunoblot assay kit were followed.
In order to determine the antibody responses of cattle immunized with purified glycoproteins, the ELISA
was performed essentially as described previously. van Drunen Littel-van den Hurk et al. (1984), supra.
However, affinity-purified, peroxidase-conjugated rabbit anti-bovine IgG (Zymed) at a dilution of 1:3000 was used as the detecting antibody.
The neutralization titers of the bovine sera were determined as described previously. Babiuk et al.
(1975), supra. To determine complement-enhanced neutralization, guinea pig serum (1:40 final dilution) was added to the virus-antibody mixture. The titers were expressed as the reciprocal of the highest dilution of antibody which caused a 50~ reduction of plaques relative to the virus control.
ADCC assays were performed in microtiter plates as described previously. Babiuk et al. (1975), supra.
The ratio of effector cells (polymorphonuclear cells) to target cells (BHV-l-infected, 51Cr-labeled GBK cells) was 50:1. Controls consisted of BHV-l-infected GBK target cells plus anti-BHV-l serum or targets with polymorphonuclear cells in the absence of antibody.
I.A.6. Clinical Evaluation and_Necropsy The clinical evaluations were performed at the same time each day by two independent investigators who were uninformed about the specific treatments of the individual animals. The parameters evaluated included depression, appetite, fever, conjunctivitis, rhinitis, mouth-breathing, tracheitis, and pneumonia. In each case a score of 0 was assigned ~o healthy animals. Clinical scores of 1-4 were assigned to sick animals for each individual parameter as follows: 4, severe; 3, marked;

RB~S06FO . WP .12 29310-20005.20 Client ID None PATENT

2, moderate; 1, mild. Total clinical scores for each animal are the sums of scores for each parameter.
Postmortem examinations were done on animals that died or were euthanized during the experiments. The nasal passages, larynx, trachea, and lungs were examined and photographed. Viral and bacterial lesions were recorded. The extent of pneumonia was assessed by a numerical method developed by Thomson et al. (1975) Canad. J. Comp. Med. 39:194-207. The pneumonic lesions in each lung lobe (except for the accessory lobe) were graded from 0 to 5 according to the amount of tissue involved. Total scores for seven lung lobes ranged from 0 to a theoretical maximum of 35 if the entire lung was affected.
I.A.7. ~eukocyte Function To study post-BHV-1-challenge leukocyte func-tion, venous blood was collected into syringes containing citrate dextrose. The blood was centrifuged at 1000 g for 20 min, the buffy coat was collected, and the peripheral blood mononuclear leukocytes (PBL) were further purified on Ficoll-Hypaque as described previously. ~3ielefeldt Ohmann et al. (1985), supra. The polymorphonuclear neutrophils (PMN) were isolated from the original pellet by lysis of the erythrocytes as described previously. The viability of both PBLs and PMNs was greater than 99~ as determined by trypan blue exclusion.
(i) Functional Analysis of PB~. Lectin-driven lymphocyte proliferation was assayed as described previ-ously. Id. sriefly, 1 x 105 PBL were added into quadruplicate wells of a flat-bottomed microtiter plate (Nunc, Roskilde DK) in a final volume of 200 ~l of RPMI
1640 plus 5% fetal bovine serum, 50 mM HEPES, and 25 mg gentamycin (all media components are from Grand Island RBNS06FO . WP .12 ~ , . . .

,. . . . . .

: ":

29310-20005.20 Client ID None PATENT

Biological Co., Grand Island, NY). Lectins, phytohemagglutinin (PHA), and concanavalin A (Con A, Calbiochem, La Jolla, CA) were added to the cultures.
The cultures were incubated for 72 hr and labeled with [methyl-3H]thymidine (H3-Tdr) (~nersham Co., Oakville, Ontario) during the last 16-18 hr of incubation. The amount of radioactivity incorporated by PB~s was quantitated by liquid scintillation counting.
(ii) Functional Analysis of PMNs. Chemotaxis of PMNs was measured using microchemotaxis chambers. Gee et al. (1983) Proc. Natl. Acad. Sci. USA 80:7215-7218.
Briefly, 25 ~l of the chemoattractant was added to the bottom wells of the chemotaxis chamber, whereas the top chamber wells contained 45 ~l of PMNs. The chemotaxis chambers were incubated for 2 hr in a humidified CO
atmosphere at 37C. ~fter incubation, the membranes were removed and nonmigrating cells were scraped from the upper surface. Membranes were fixed, stained with Giemsa, and examined microscopically for the presence of migrating cells. Cell counts are presented as the mean counts of three representative high-power microscope fields.
Luminol-enhanced chemiluminescence was measured by the method of Abramson et al. (1982). ~riefly, 2 x cells were added to vials containing 5 ml of Hank's balanced salt solution, 400 ~l of opsonized zymosan, and 20 ~l of luminol. Immediately upon addition of the cells, the reaction was followed over time using a Packard Picolite 6500 Luminometer (United Technologies Packard, Downers Grove, IL). Results are plotted as CPM/10 cells at the peak of the response which occurs at 45 min.
Superoxide anion generation and release were measured by the superoxide dismutase (SOD) inhibitable reduction of ferracytochrome C as described previously.

RB~S06FO .WP .12 : . - ,.

- :- ~ ' , ' 29310-20005.20 Client ID None PATE,NT

Johnson et al. (1978) J. Exp. Med. 148:115-127. All samples were assayed in duplicate and in suspension in a final volume of 1 ml. The samples were incubated for 45 min at 37C. The reaction was terminated by transferring 1 ml aliquots to an ice bath followed by centrifugation.
The cytochrome c reduction was monitored on a spectrophotometer at 550 nm. The OD value was then co~verted to nm 02/cell.

I.B. Results I.B.1. Immune Responses to Purified Glycoproteins As explained above, the purified native BHV-1 glycoproteins were tested for their ability to induce protective immune responses in cattle. Figure 1 indicates that within 10 days of immunization, all of the individual glycoproteins or combinations thereof induced detectable serum neutralizing titers. ~ollowing a booster immunization 21 days later, there was a further increase in the level of serum neutralizing antibodies induced by the glycoproteins. Highest responses were present in those animals immunized with gIV. In contrast, animals immunized with a commercial killed ~HV-1 vaccine produced marginal antibody titers within 10 days of immunization. This antibody level decreased to preimmunization levels by 20 days after immunization.
Following a second immunization with the commercial vaccine, antibody titers were boosted to approximately the level observed 10 days postimmunization with the purified glycoprotein. In no case did the placebo-vaccinated animals develop any immune responses.
To measure the speci~icity of the immune response, the serum from each animal was tested by an ELISA using individual glycoproteins as the antigens.
Animals immunized with gI only reacted in the ELISA when S06FO.WP .12 ~, .
: . `; - , : ~ ` ~ . , ,: ' ~. :.:: :: :

, . , ` . ~ : :
~` : : :: : ` ~ :
- : :, `
:. . ' ~ , ' :, ' ! -29310-20005.20 Client ID None PATENT

gI antigen was used to coat the plate. In contrast, those animals that were immunized with gIII only reacted with gIII coated plates. Similarly, animals immunized with gIV only recognized gIV. Tllese results also indicate, similar to Figure 1, that the animals immunized with gIV had higher titers than did animals immunized with the other glycoproteins. To confirm that the animals only reacted with the specific glycoproteins with which they were immunized, Weste:rn blot analysis was performed using the sera from the individual animals.
Animals immunized with gI, gIII, or gIV reacted only with their respective glycoproteins in immunoblot assays.
These results further indicate that the animals were not accidentally exposed to a field strain of BHV-1 during the immunization period.
Since the sera from animals immunized with glycoproteins were specific for the individual glycoproteins used for immunization and could neutralize virus infectivity in vitro, attempts were made to determine whether any one of the individual glycoproteins could induce antibody capable of participating in ADCC.
The results of Figure 2 indicate that ADCC titers, although higher than SN titers, do parallel the serum neutralizing titers. Thus, animals immunized with gIV
had higher ADCC titers than did animals immunized with the other glycoproteins, those immunized with gI being marginal in killing. Again, animals immunized with the commercial killed BHV-1 vaccine exhibited a marginal response.
I.B.2. Protection Studies Prior to challenge with BHV-1 and P.
haemolytica, all animals were healthy and had a normal rectal temperature. However, within 48 hr post-BHV-1 infection, animals started exhibiting a rise in RBNS06FO . WP .12 `' . : ` ;: - ` ,: ': - ' : :, :` `

29310-20005.20 Client ID Mone PATENT

temperature. Temperature responses continued to increase until they reached peak levels 4-7 days post-BHV-l infec-tion. In each case, animals within the groups immunized with the glycoproteins exhibited much lower temperature responses than did the placebo or animals im~unized with the commercial whole virus vaccine. In addition to temperature responses, a variety of other parameters of respiratory distress were assessed. A clinical score of 10 or greater was set to indicate severe respiratory disease, which under field conditions would result in isolation of the animal and treatment to prevent pneumonia and subsequent death. Figure 3 indicates the total number of sick days (clinical score greater than 10) for the five animals within each individual treatment group. Animals immunized with individual glycoproteins or combinations thereof exhibited fewer days of morbidity than did the whole virus- or placebo-immunized animals.
All glycoprotein groups were significantly different from placebo groups. No significant difference was present between placebo and animals immunized with the commercial vaccine.
Since the individual glycoproteins provided relatively good protection against severe respiratory disease, attempts were made to determine whether intra-muscular immunization with individual glycoproteins hadany effect on the extent of virus shedding from the nasal passages. All five of the placebo treated animals shed virus for the entire observation period, beginning from Day 2 to Day 10 post-BHV-l challenge. In contrast, animals immunized with the glycoproteins shed virus for a significantly fewer number of days (P~0.005 Fisher exact test). Once again, animals immuni ed with the com~ercial vaccine shed virus for more days than did animals im-munized with individual glycoproteins (not significantly different from controls).

RBNS06FO . WP .12 29310-20005.20 Client ID None PATENT

In the present model, mortality rates of nonimmunized animals generally ranges from ~0 to 80~.
The mortality rate of placebo immunized animals in this particular experiment was 60~, whereas it was 40~ in those immunized with the commercial vaccine. However, none of the animals immunized with the individual or glycoprotein combinations died. In an attempt to confirm that immunization with glycoproteins did induce protection and reduced lung involvement, the lungs of the animals were collected and assessed for the extent of pneumonia. The data demonstrate that the reason for the reduced morbidity of glycoprotein-immunized animals was that there was minimal infection of the lower respiratory tract. No specific glycoprotein group had more severe lung lesions or greater weight loss than the others indicating equal protection by all glycoproteins.

I.B.3. Leukocyte Functions BHV-1 causes a significant reduction in leukocyte functions between 4 and 8 days postinfection.
This immunosuppression is directly correlated to the extent of virus replication and is responsible for the secondary bacterial colonization which results in severe pneumonia. To determine the effect of immunization with various glycoproteins on macrophage functions, peripheral blood macrophages were assayed for their chemotactic response to a chemotactic agent (activated bovine serum as a putative source of C5a). Although macrophage chemotaxis was reduced in all animals, the animals immunized with the various glycoproteins had a lower degree of suppression at 5 days post-BHv-1 infection and rapidly returned to normal by 10 days postinfection. In contrast, immunosuppression was more dramatic and remained for a longer period of time in the placebo-treated animals and those immunized with the RBNS O 6FO . WP .12 - :, , :

29310-20005.20 Client ID None PATENT

commercial vaccine. A similar pattern was observed in the case of PMNs. It is interesting to note that although there were no significant differences between the placebo and animals immunized with the commercial vaccine, these animals were actually more suppressed than was the placebo group, indicating that the vaccine does not induce significant protection from immunosuppression by BHV-1. This suggests that the level of antibody and cell-mediated immunity generated by the commercial vaccine is below protective levels. This i9 supported by the observation that lymphocyte blastogenesis was also suppressed in the commercial vaccine and placebo-immunized animals, whereas those immunized with any individual or combination of glycoproteins were not.
A further indication of neutrophil function was determined by measuxing the ability of PMNs to produce supero~ide. The PMNs from glycoprotein immunized animals produced similar levels of superoxide throughout the observation period. In contrast, the placebo group or animals immunized with a commercial vaccine had a significant reduction in their ability to produce superoxide. This reduction was a gradual decline such that by Day 10 their superoxide production capabilities were reduced to less than 30~ of preinfection levels. A
further indication of neutrophil function was demonstrated in a chemiluminescence assay. In this assay, instead of measuring one oxygen radical, the assay measures the ability of neutrophils to produce a number Gf toxic oxygen species. In this case, the glycoprotein-immunized animals did not demonstrate any significant increase in chemiluminescence for 5 days after BHV-1 infection. By 7 days post-BHV-1 infection there was an increase in chemiluminescence which began dropping by 10 days postin~ection. In contrast, the placebo-treated animals and those immunized with the R~3NS06FO . WP .12 : :

``,.
.

29310-20005.20 Client ID None PATENT

commercial vaccine began to have elevated chemiluminescence responses 5 days post-BHV-1 infection.
These levels were extremely elevated by 7 days postinfection and began to decline by 10 days postinfection.

This example demonstrates the production of non-native BHV-1 subunit antigens in recombinant vaccinia virus vectors.

II.A. Methods II.A.1. Cells and Viruses Strain P8-2 of BHV-1 was propagated in Georgia bovine kidney (G8K) cells and quantitated by plaquing in microtiter plates with an antibody overlay as described previously. Rouse et al. (1974) J. Immunol.
113:1391 1398. Vaccinia virus (VAC) (WR strain) and recombinant vaccinia virus wag propagated in BSC-1 or BSC-40 cells. Madin Darby bovine kidney (MDBK) cells, BSC-1 and -40 cells, bovine fibroblasts (~FB), bovine tracheal cells (BTB) and human thymidine kinase-negative (TK ) 143 cells were grown as monolayers in Eagle minimal essential medium (MEM) (Grand Island Biological Co., Grand Island, NY), supplemented with 10~ fetal bovine serum (FBS) (Grand Island Biological Co.).

II.A.2. Preparation of DNA
All DNA used for ligations and transfections was CsCl gradient purified and set to concentrations of 1 ~g/~l in 10 mM Tris ~pH 7.5], 1 mM EDTA. Maniatis et al.
(1984), supra.

RBNSO 6FO . WP .12 29310-20005.20 Client ID None PATENT

II.A.3. Transfection and Isolation of Recombinant Viruses Recombinant vaccinia viruses were selected by marker rescue as previously described. Wier et al.
(1982) Proc. Natl. Acad. Sci. USA 79:1210-1214.
Approximately 3 x 106 BSC-40 cells (thymine kinase-positive -TK+) were infected with wild-type vaccinia virus (WR strain) at a multiplicity of infection (MOI) of 0.03 PFU per cell. At 4 h postinfection approximately 15 ~g of CaC12-precipitated (125 mM) linearized plasmid DNA (i.e., pgB vax, Figure 8; or pgC
vax, Figure 10) was added to the infected BSC-40 cells.
After 4 days of incubation at 37C, viruses were harvested from cell supernatants following two cycles of freezing and thawing. Several dilutions of sonicated virus supernatants were plated on TK 143 cells and then overlaid with 1% agarose in growth medium contai.ning 5-bromo-2' deoxyuridine (25 ~g/ml) to select for TK
virus. After three days individual TK plaques were removed and virus from these plaques was plated on BSC-40 cells. Putative recombinant viruses were repurified by plaquing on BSC-40 cells. Individual plaques were amplified by growth on BSC-40 cells and virus supernatants were tested for the presence of gI and gIII
proteins by ELISA using polyclonal rabbit antisera specific for either gI or gIII.

II.A.4. Preparation of Radiolabeled Cell Lysates BSC-1, MDBK, BFB or BTB cells were infected with BHV-1, VAC, VAC-I or VAC-III at an MOI of 10. After adsorption of the virus for 1 h, the monolayers were overlaid with either methionine-free or glucose-free ~M
(Grand Island Biological Co.) containing 2~ FBS (Grand Island Biological Co.) and further incubated at 37C.
Where applicable, tunicamycin was added, immediately RBNSO~FO . WP .12 , , ' ' :

293:L0-20005.20 Client ID None PATENT

after virus adsorption. Six hours after infection, 50 ~Ci of L-[35S] methionine or 50 uCi of [3H] glucosamine (Amersham, Oakville, Ont.) per ml was added to the cultures. At 24 h postinfection, the cells were harvested and washed with phosphate-buffered saline (PBS:
0-01 M NaH2PO4/Na2Hpo4, 0.15 M NaCl, pH 7.4). In time course experiments, BHV-1-, VAC-, VAC-I- or VAC-III-infected BSC-1 cells were labeled with L-[35S]
methionine immediately after virus adsorption and harvested at various times after infection. To increase the incorporation of isotopically labeled methionine, the cells were grown in methionine-free MEM for 6 h before infection. In pulse-chase experiments the cells were overlaid with methionine-free MEM after virus adsorption.
At 6 or 12 h postinfection, the cells were pulse-labeled for 15 min with 200 ~Ci of L-[35S] methionine in Hanks balanced salt solution (HBSS) (Grand Island ~iological Co.). The cells were either harvested immediately or the label was first chased for 2 h by washing and incubating the cells in MEM containing 100 ~g of cycloheximide per ml. To prepare lysates, the cells were suspended in modified RIPA buffer (0.02 M Tris-hydrochloride [pH a.0], 0.15 M NaCl, 1% sodium deoxycholate, 1~ Nonidet P-40), left on ice for 15 min and sonicated for 15 s at a setting of 100 on a sonifier cell disrupter (Model 1510 Braunsonic Braun, Melsunger, A.G., Germany). The suspensions were clarified by centri.fugation at 20,000 rpm for 15 min in a 30 A100 rotor at room temperature (Airfuge, Beckman Instruments, Inc., Fullerton, CA). The supernatants were used immediately for immunoprecipitation as described in Example I.

II.A.5. SDS-PAGE and ELISA
Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was perfo*med in 7.5%

RBNS06FO .WP .12 `:

`, `~: ' 29310-20005.20 Client ID None PATENT

polyacrylamide discontinuous gels as described in Example I. Electrophoresis was carried out under reducing condi-tions. Samples containing 35S were analyzed by autoradiography of the gels on 3M X-ray film (Picker, Saskatoon, Sask.). Gels containing 3H were impregnated with Amplify (Amersham), dried and analyzed by fluorography at -70C. The molecular weights of the polypeptides were estimated from the molecular weight markers (BioRad, Mississauga, Ontario) that were electrophoresed in parallel with the samples.
In order to identify recombinant vaccinia virus, expressing gI or gIII, an indirect ELISA was performed essentially as described in Example I.
Microtiter plates were coated with cell extracts prepared from recombinant TK virus-infected BSC-40 cells and reacted with gI- or gIII-specific rabbit sera.
Affinity-purified, horse-radish peroxidase (HRPO)-conjugated goat anti-rabbit IgG
(Boehringer-Monheim, Dorval, Quebec) was used at a dilu-tion of 1:2000 for detection.
A sandwich ELISA was used to compare the yield of glycoproteins gI and gIII from recombinant-infected cells to that from BHV-l-infected cells. Microtiter plates were coated with a mixture of monoclonal IgG as the captive antibody and then incubated with lysates from recombinant- or BHV-l-infected cells. A mixture of HRPO-conjugated monoclonal antibodies with a different epitope specificity was used for detection.

II.A.6. Cell Surface Immunofluoresence BSC-l cells were infected with BHV-l, VAC, VAC-I or VAC-III at an MOI of 10. After 20 h at 37C, the cells were removed by mild trypsinization and 1 x 106 cells were resuspended in 250 ~1 of 1:20 diluted rabbit antiserum, specific for gI or gIII. After reaction for RBNS06FO . WP .12 : : . .

29310-20005.20 Client ID None PATENT

45 min on ice, the cells were washed three times in HBSS
and incubated with a 1:10 dilution of fluorescein-isothiocyanate-conjugated goat anti-rabbit IgG antiserum (Cappel Laboratories, West Chester, PA).
After further reaction for 45 min on ice, the cells were washed three times in HBSS and f:Lnally resuspended in 10 glycerol-PBS, mounted on glass s:Lides and observed with the aid of a fluorescence microscope.

II.B. Recombinant Production of qI and gIII in a Vaccinia Vector II.B.1. Construction of ~accinia Virus Insertion Plasmids The gI gene maps between 0.422 and 0.443 genome equivalents (Figures 4 and 5), which is within the BHV-1 HindIII A fragment described by Mayfield et al. (1983), supra. A KpnI plus AccI partial digestion of the HindIII
A fragment produces a 325~ base pair (bp) subfragment which contains the entire gI gene coding sequence. DNA
sequence analyses placed an AccI site 20 bp 5' to the ATG
start codon, while the KpnI site is 420 bp 3' to the TGA
stop codon. This fragment was inserted into a synthetic DNA polylinker present between the EcoRI and SalI sites of PBR328 (i.e., ppol26, not shown) to produce pgB
complete. To this end, the AccI asymmetric end of the 3255 bp fragment was first blunted with Klenow enzyme and the gI fragment was then ligated to the HpaI p~us KpnI
sites of ppol26 to give pgB complete. HpaI and KpnI
sites are within the polylinker of ppol26 and are flanked respectively by a BglII and a BamHI site. The gI gene was then transferred from pgB complete as a 3260 bp BglII
+ BamHI fragment to the BamHI site of the vaccinia virus insertion vector pGS20 to generate pgB vax (Figure 8;
plasmid pGS20 with gI gene). Moss et al. in Gene RBNS06FO . WP .12 .
- ~

::

- ' ' ' ` ' ' ,~`~ , `

29310-20005.20 Client ID None PATENT

Amplification and Analysis, Vol. 3, pp. 201-213 (Papas et al. eds. 1983).
The BE~-1 gIII gene maps between 0.120 and 0.131 genome equivalents (Figures 4 and 6) which lay within the BHV-1 HindIII I fragment. Mayfield et al.
tl983), supra. The entire gene is contained within a 3090 bp BglII + EcoRI subfragment of HindIII I which was cloned into the EcoRI plus BamHI sites of ppol26 to yield pll3R1 Bgl 3.0 (Figure 9). The gIII gene was transferred to the BamHI plus SmaI sites of pGS20 as a 2550 bp EcoRI
+ BamHI subfragment of pll3R1 Bgl 3.0 to generate pgC vax (Figure 10; plasmid pGS20 with gIII gene). The Bam~II
site of the gIII gene subfragment is 50 bp upstream from the ATG start codon while the EcoRI site which was blunted with Klenow enzyme prior to ligation is 920 bp downstream from the TAG stop codon.

II.B.2. Construction of Recombinant Vaccinia Virus The two plasmids pgB vax and pgC vax were then used to transfect BSC-40 cells infected with wild-type vaccinia virus (WR strain). Homologous recombination between vaccinia TK sequences in the plasmid and virus genome resulted in the insertion of the gI or gIII gene into vaccinia virus. Recombinant vaccinia viruses putatively expressing BHV-1 gI or gIII were selected as TK plaques produced on TK 143 cells in the presence of 5-bromodeoxyuridine, following recovery of recombinant virus from the initial BSC-40 cell infection.
Recombinant vaccinia virus actually expressing BHV-1 gI
or gIII was identified by screening TK virus in an EhISA. Infected cell extracts from recombinant TK virus were immobilized on microtiter plates and reacted with serial dilutions of gI- or gIII-specific rabbit sera.
ELISA-positive infected cell extracts were used for further studies.

RB~S06FO . WP .12 ~ . ~ ' ' ::

293:L0-20005.20 Client ID None PATENT

II.B.3. Analysis of Recombinant Virus DNA
To insure proper gene insertion, putative re-combinant virus DNA was isolated, digested with restric-tion endonucleases known to cut within the BHV-1 gene inserts, run on agarose gels and transferred to nitro-cellulose by the methods of Southern (1975) J. Mol. Biol.
98:503. Southern transfers were then probed with 32P-labeled nick-translated gI and gIII gene fragments.
The order and size of the fragments generated from the recombinant viruses were consistent with those predicted by the DNA sequence analyses of the gI and gIII genes.

II.B.4. Analysis of Glycoproteins Made in Recombinant-Infected Cells To examine the protein products translated ln vitro from the BHV-1-specific transcripts, BSC-1 cells were infected with BHV-1, WR vaccinia virus (VAC), vaccinia recombinant VAC-I or vaccinia recombinant VAC-III and labeled with L-[35S] methionine. The radiolabeled proteins were immunoprecipitated with gI-specific monoclonal antibody lE11 or gIII-specific monoclonal antibody lD6, and analyzed by SDS-PAGE under reducing conditions.
Monoclonal antibody lE11 precipitated three major glycoproteins from BSC-1 cells infected with re-combinant VAC-I, but did not react with any proteins from mock-, VAC-, or VAC-III-infected cells. These glycoprotein species comigrated exactly with authentic BHV-1 glycoproteins pgIa ~117K), gIb (74K) and gIc (55K).
BHV-1 glycoprotein gIa, the uncleaved counterpart of gI~
and gIc, was not found in recombinant VAC-I-infected cells, indicating a difference in the efficiency of processing. Glycoproteins gIa and gIb, which have apparent molecular weights of respectively 130K and 74K

RBNS06FO . WP .12 . ' , , ' ' ,~

29310-20005.20 Client ID None PATENT

in MDBK or GBK cells, appeared to have slightly lower molecular weights of 127K and 71K in BSC-1 cells.
Similarly, monoclonal antibody lD6 precipitated a unique glycoprotein from BSC-1 cells inf.ected with recombinant VAC-III, which comigrated with authentic BHV-1 glycoprotein gIII. This antibody did not react with any proteins from mock-, VAC- or VAC I-infected cells.
Although this glycoprotein has an apparent molecular weight of 91K in MDBK and GBK cells, it appeared to have a molecular weight of 85K in BSC-l cells. The observed shifts in apparent molecular weights were probably due to a difference in the extent of glycosylation.
Several other cell lines, both permissive and non-permissive for vaccinia replication, were tested for the production of BHV-l glycoproteins after infection by VAC I or VAC III. BFB and BTB cells, permissive for vaccinia replication, both produced the same species of sHV-l glycoprotein, when infected with recombinant VAC-I
or VAC-III. In addition to gIII, its precursor, pgIII
(69K) was detected in BHV-l-infected BFB and BTB cells, indicating that in these cells recombinant-produced gIII
is processed at a faster rate than its authentic counter-part. However, in MDBK cells, which are nonpermissive for vaccinia growth, no expression of the glycoproteins was observed.
These data demonstrate that the two recombinant vaccinia viruses produce BHV-l glycoproteins gI and gIII
and their electrophoretic mobility suggests that they are fully glycosylated. In support of this conclusion, ~SC-l cells were infected with BHV-1, VAC-I, or VAC-III, labeled with [3H] glucosamine and analyzed by immunoprecipitation followed by SDS-PAGE. This experiment confirmed that recombinant and authentic glycoproteins ~I and gIII were glycosylated in a similar, if not identical, manner.

RBNS06FO .WP .12 .,; : ~

29310-20005.20 Client ID None PATENT

II.B.5. ~uantitation of Glycoproteins Produced in Recombinant-Infected Cells In order to quantitate the amounts of re-combinant glycoprotein produced in different cell lines,a sandwich ELISA was performed. Cell lysates were prepared from cells infected with BHV-1, VAC-I or VAC-III
and assayed with respect to production of glycoproteins gI and gIII. Table 1 shows that l~DBK is the cell line of choice for producing large quantities of BHV-1 glycoproteins, followed by BTB, BFB and BSC 1 respectively. In contrast, BSC-1 is the better cell line for VAC-I and VAC-III, followed by BFB and BTB. MDBK
cells infected with VAC-I or VAC-III did not produce any glycoproteins, which is in accordance with the nonpermissiveness of this cell line for vaccinia replication. A comparison of the best producing cell lines for each virus, i.e., MDBK for BHV-1 and BSC-1 for VAC-I and VAC-III, showed that authentic gI and gIII were produced in approximately a 6-fold excess over recombinant gI and gIII.
Since the highest quantities of recombinant gI
and gIII, as well as sufficient amounts of authentic gI
and gIII, were produced in BSC-1 cells, these cells were used for all subsequent experiments.

RBNS06FO .WP .12 - , ' ~ - ~ ,, , 29310-20005.20 Client ID None PATENT

Table 1 ELISA Titera in Cell Line S Virus ~ qIII qI ~ qI qIII qI qIII
None 16 16 4 16 16 16 4 4 VAC 4 4 4 16 4 4 ~ 4 4 VAC-III c 4 190 4 16 4 30 c 4 25 aELISA titers were expressed as the reciprocal of the highest dilution that still gave a reading of at least O .1.
II.B.6. Posttranslational Modifications of BHV-1 Glycoproteins Two lines of evidence suggest that the authentic and recombinant glycoproteins gI and gIII are glycosylated to the same extent. First, they comigrated in one-dimensional polyacrylamide gels and secondly, they incorporated [3H] glucosamine in an identical fashion.
To support these observations, two additional experiments were performed.
The effect of tunicamycin, a drug which inhibits N-linked ~lycosylation, on the processing of gI
and ~III was investigated. In the presence of 1 ~g of tunicamycin per ml, the nonglycosylated precursor form of gI, pI (105K) was synthesized in BSC-1 cells infected with either VAC-I or BHV-1 and immunoprecipitated by monoclonal antibody lE11. Since the nonglycosylated precursor forms comigrated, this ~uggests that the polypeptide backbones of authentic and recombinant gI are identical. Consequently, the fact that the glycosylated RBNS06FO .WP .12 .

,` , ;, . . . `

293:L0-20005.20 Client ID None PATENT

products of VAC-I and BHV-l also comigrated, provides further support for similar or identical glycosylation.
In the presence of 0.1 or 1.0 ~g/ml of tunicamycin, a polypeptide o~ 77~C was detected in BSC-l cells, infected with either VAC-:[II or BHV-l and immunoprecipitated with monoclonal antibody lD6. Since gIII contains O-linked carbohydrates, this species does not correspond to the nonglycosylated precursor, but to a partially glycosylated product, containing only O-linked carbohydrates. These species comigrated in VAC-III- and BHV-l-infected BSC-l cells, suggesting that the N-linked and O-linked glycosylated processes are similar if not identical for both products.
The order and time course of synthesis of gI
and gIII was investigated in a second series of experiments. BSC-l cells were infected with BHV-l, VAC-I
or VAC-III, labeled with L-[35S] methionine immediately after virus adsorption and harvested at 2 h intervals after infection. Cell lysates were prepared and precipitated with monoclonal antibody lEll or lD6. These experiments demonstrated that both recombinant and authentic gI were synthesized as early as 2 h postinfection. Recombinant gIII was also detected at 2 h after infection, but authentic gIII was not present until 8 h postinfection.

II.B.7. Cell Surface Expression of BHV-l Glycoproteins Expression of glycoproteins gI and gIII on the cell surface was examined by indirect immunofluorescence of recombinant- or BHV-l-infected live BSC-l cells. At 20 h postinfection, the cells were incubated with either gI- or gIII-specific rabbit serum. The recombinant-derived glycoproteins had a patchy appearance over the entire cell surface, which was similar to the pattern observed for BHV-l-infected cells. The RBNSO 6FO . WP .12 `. , : ' ~' ` :
.

"

:

29310-20005.20 Client ID None PATENT

fluorescence caused by recombinant gIII was stronger than that of recombinant gI.

II.C. Recombinant Production of gIV in a Vaccinia Vector II.C.1. Construction of the p WSL-1 Insertion Vector The p WSL-1 insertion vector was constructed as depicted in Figures 11 and 12. Specifically, the pW-1 expression vector was derived from the pGS-20 plasmid (Figure 9; van Drunen Littel-van den Hurk et al. (1989) J. Virol. 63:2159-2168). pGS-20 was digested with XhoI
and AvaI and then ligated. This process resulted in the deletion of a 2,200 bp fragment and the production of p W-1 (Figure 11).
p WSL-1 was then constructed from elements of pW-1 and a series of four synthetic oligonucleotides representing an adenine rich region, a spacer and a consensus sequence from the vaccinia virus late gene promoter. (This consensus sequence, T~AAT, was based on a sequence described by Davison and Moss (1989) J. Mol.
Biol. 210:771-784.) A 3,080 bp EcoRI-PstI fragment and a 1,700 bp SmaI-PstI fragment were isolated from restriction enzyme digests of p W-1. The fragments were then ligated together with the four oligonucleotides to form p WSL-1. The p WSL-l has two unique cloning sites;
BglII or BglII + SmaI (Figure 12).

II.C.2. Insertion of the Full-Length BHV-1 qIV Gene into p WSL-1 The procedures for gene insertion and recombinant vaccinia virus recovery were the same as that described for pGS-20. (See, van Drunen Littel-van den Hurk et al. (1989) J. Virol. 63:2159-2168.) The BHV-1 gIV sequence shown in Figure 7 was digested with MaeI restriction endonuclease. The RBNS06FO .WP .12 , , 29310-20005.20 Client ID None PATENT

resulting MaeI sites at sequence positions 42 and 1344 were converted to BglII sites using commercially obtained oligonucleotide linkers (Pharmacia). The resulting BglII
adapted BHV-1 gIV gene was then cloned into the BglII
cloning site of p W SL-1 to yield the expression vector p W-1/gIV (Figure 13).

II.C.3. Insertion of a Truncated BHV-1 qIV Gene into p WSL-1 The gene for BHV-1 gIV was modified to incorporate a stop codon in the reading frame immediately preceding the putative membrane spanning region of the mature protein (Figure 7). The modification of the gene results in the early termination of translation and the secretion of the truncated protein. This system eliminates the requirement for extensive downstream processing that is associated with the production of antigens that are associated with membranes, and causes an up to tenfold increase in product yield.
The BglII adapted gene for BHV-1 gIV was partially digested with SacII. Gene fragments cut at nucleotide position 1154 were identified and isolated.
The SacII site was then converted into a XhoI site using commercially obtained oligonucleotide linkers (Pharmacia). A second synthetic oligonucleotide linker was then inserted at the XhoI site to yield an in-frame stop codon. The resulting modified BHV-1 gIV gene was then cloned into the BglII cloning site of p W SL-1 to yield the expression vector p W-1/gIVt (Figure 14).
II.C.4. Purification of Recombinantly Expressed gIV
BSC-l cells were cultured in MEM containing 10 fetal bovine serum. Confluent monolayers were infected with the recombinant vaccinia, BHV-1 gIV virus, at a multiplicity of 0.1. 72 hours after infection or at the RBNS06FO . WP .12 -, : ., . ~:

29310-20005.20 Client ID None PATENT

appearance of total cytopathic effect, the recombinant gIV was harvested.
For full-length gIV, the cells were scraped from the surface of the culture flasks into the growth media, which was then centrifugecl (lOOOg for 20 min) and the cell pellet collected. The cells were disrupted with detergent and further processed as previously described.
Truncated gIV was collected by harvesting the media from the cult~lre flasks. Cell debris was removed by centrifugation at lOOOg for 20 min. The clarified media was frozen at -70C until processing. AEter thawing, the media was filtered through a 0.45 micron filter. The detergents, Nonidet P40 and NaDeoxycholate, were then added to the filtrate to final concentrations of 0.1%. The truncated gIV was then purified by affinity chromatography through BHV-1 gIV specific columns, as has been described previously.

III
This example demonstrates the production of non-native BHV-1 subunit antigens in recombinant SV40 and RSV vectors.

III.A. Materials and Methods III.A.1. Reagents and Media Restriction enzymes, T4 DNA polymerase, T4 DNA
ligase, calf intestine alkaline phosphatase, phosphorylated BglII linker oligonucleotide~, deoxynucleotide triphosphates and protein A-Sepharose were purchased from Pharmacia, Dorval, Quebec, Canada and used as recommended by the manufacturer. Other chemicals and reagents for DNA manipulations, transfections and protein analysis were purchased from Sigma Chemicals, St.
Louis, MO, and used according to the standard methods RB~S06FO . WP .12 ;.: ~ , : . . : ., ::: -` , :..

, 29310-20005.20 Client ID None PATENT

described by ~aniatis et al. (1982), supra, and Davis et al. Basic Methods in Molecular Biology (1986), except where noted otherwise below. Ce]l culture media, fetal bovine serum (FBS), G418 and other cell culture reagents were obtained from GIBCO/BRL, Burlington, Ontario, Canada. Antibodies, wheat germ agglutinin, avidin-biotin immunoperoxidase staining kits, and other reagents for enzyme immunoassays were purchased from Dimension Laboratories, Mississauga, Ontari.o, Canada and used according to the manufacturers' recommendations.
Radioisotopically labeled compounds and reagents for fluorography were purchased from Amersham, Oakville, Ontario, Canada.

III.A.2. Plasmid Construction The complete coding sequence of BHV-l gI was excised from a subclone of pSD106 (Mayfield et al. 1983, supra; the genomic library is shown in Figure 17) and inserted into the expression vector pRSVcat (Gorman et al. 1982, supra) in place of the cat gene by ligation of the 3.3 kilobase pair (kbp) BglII-BamHI gI gene fragment into the ~indIII-HpaI sites of pRSV cat after the latter sites had been converted into a unique BglII cloning site by blunt end repair, BglII linker addition, and BglII
digestion (Figure 15A). The gI gene was similarly subcloned into the expression vector pSV2neo (Southern et al. 1982, supra) in place of the neo gene by ligation of the 3.3 kbp BglII-BamHI gI gene fragment into the HindIII-SmaI sites of pSV2neo after the latter sites had been co~verted into a unique BglII cloning site as described for pRSVcat (Figure 15B).
The complete coding sequence of BHV-l gIII was excised from a subclone of pSD113 (Mayfield et al.
(1983), supr_) as a 2.4 kbp BamHI-EcoRI fragment treated with T4 DNA polymerase, ligated to BglII linkers, I~BNS06FO . WP .12 : . '`' : : .

- ; . ' .: : . : ~ ' -. ~

29310-20005.20 Client ID None PATENT

digested with BglII then cloned into pRSVcat and pSV2neo as described for BHV-1 gI.
Plasmid DNA was prepared for transfection by equilibrium banding in CsC1-ethidium bromide gradients and sterilized by ethanol precipitation.

III.A.3. Cells and Virus Madin-Darby bovine kidney (MDBK) and murine 3T3 cells were cultured in Eagle's minimal essential medium supplemented with 10~ FBS. Murine LMTK and L929 cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 5~ FBS. virus stocks of BHV-1 strain P8-2 were ~rown in MDBK or Georgia bovine kidney cells as previously described in Example I. Virus stocks of vaccinia virus strain WR were grown in ~SC-1 cells as described in Example II.

III.A.4. Transfections LMTK cells were transfected with expression plasmid constructions by a modified calcium phosphate precipitation procedure. LMTK cells at approximately 50% confluence were rinsed and incubated at 37C in fresh growth medium for 3 h before transfection. Calcium phosphate precipitates of plasmid DNA were prepared as previously described with pSV2neo DNA incorporated into each precipitate as a co-transfecting selectable marker.
Graham et al. (1973) Virology 52:456-467; Wigler et al.
~1979) Proc. Natl. Acad. Sci. USA 76:1373-1376. Control precipitates were prepared with pSV2neo or salmon sperm DNA only. Medium was removed from the cells and the DNA
precipitates were added and adsorbed for 45 min at room temperature. Growth medium was then added and adsorption continued at 37C in a 4~ CO2 atmosphere. Chen et al.
(1987) Mol. Cell. Biol. 7:2745-2757. After 4 h the medium was removed and the cells were exposed to 20 RBNS06FO.WP .12 . : ` . --: ~ .. , , :.

29310-20005.20 Client ID None PATE'NT

glycerol shock for 2 min at room temperature then incubated at 37C in growth medium supplemented with 8 mM
Nabutyrate. Frost et al. (1978) Virology 91:39-50;
Gorman et al. (1983) Nucleic Acids Res. 11:7631 7648.
After 16-24 h the supplemented medium was removed and replaced by growth medium for 48 h. Cells were then passaged in selective growth medi~ containing 400 ~g of G418 per ml which was replaced e~ery 3 to 5 days.
Resistant colonies appeared in lO to 14 days at a frequency of approximately 10 3 using this method. The colonies derived from each transfection were pooled and cloned by limiting dilution at least once before screening.

III.A.5. Immunocytochemistry and Enzyme Linked Immunosorbent Assays G418 resistant LMTK cell clones were seeded onto glass chamber slides (Miles Laboratories, Rexdale, Ontario, Canada) and 96 well plastic tissue culture plates (Nunclon, Roskilde, DK) which had been precoated with 2 ~g of poly-L-lysine hydrobromide per cm2, and grown to confluence. For BHV-1 infected control cells, MDBK or LMTK cells were similarly seeded onto poly-L-lysine coated slides and plates, grown to 80%
confluence and then infected with BHV-1 at a multiplicity of infection of 1. After 1 h adsorption at 37C, fresh medium containing 2% FBS was added and incubation was continued for a further 12 to 18 h, for MDBK cells, or for a few minutes, for infected LMTK cells. Transfected LMTK cell clones and control cells were either fixed and permeabilized with methanol at -20C for 15 min and washed in Hank's balanced salt solution (HBSS) or, for surface expression studies, washed in HBSS without fixing. Nonspecific binding sites were blocked by adding heat inactivated normal equine serum diluted 1:75 in HBSS

RBNS06FO . WP .12 .. : ~' : ~ . :, ..
' ~: . . ~ : . : - . ` ' ,.

`` ~ , ' . ' , 29310-20005.20 Client ID None PATENT

and incubating at room temperature for 1 h. The blocking solution was removed and biotinylated wheat germ agglutinin, or monoclonal antiboclies specific for gI and gIII were diluted 1:1,000 in HBSS, and added to the slides and plates, which were incubated at room temperature for 1 h. The slides and plates were then processed with an avidin-biotin enhanced immunoperoxidase assay kit specific for mouse IgG (Vector Laboratories, Burlingame, CA) according to the manufacturer's recommendations up to the final substrate development step. For slides, the final substrate was 50 mM Tris hydrochloride, pH 7.5, 0.01~ H202, 1.7 mM NiC12, and 1 mg 3,3'-diaminobenzidine tetrahydrochloride per ml. The substrate reaction was stopped after 5 min incubation at room temperature by rinsing the slides in tap water. For enzyme linked immunosorbent assays (ELISAs) the final substrate was 0.1 M citric acid, pH 4.0, 0.015~ H2O2, and 1 mg ABST (2,2'-amino-di-~3-ethylbenzthiazoline sulfonate(6)] per ml. The ELISA substrate reactions were stopped after 5 to 10 min incubation at room temperature by addition of sodium dodecyl sulfate (SDS) to a final concentration of 5% and the absorbance of each well was read at 405 nm in a microtiter plate reader.

III.A.6. Radioimmunoprecipitation To radiolabel cellular proteins, clones or transfected LMTK cells at approximately 80~ confluence were incubated in methionine free DMEM supplemented with 2~ FBS at 37C for 6h. For glycosylation inhibition studies, tunicamycin was included at this point at a final concentration of 2 ~g per ml. After 6 h of incubation, ~35S] methionine was a~ded to a final concentration of 50 uCi per ml and the cells were then incubated for an additional 18 h. BHV-1 infected MDBK
cells were radiolabeled by a similar method as previously RBNS06FO . WP .12 , ' , .

29310-20005.20 Client ID None PATENT

described. van Drunen Littel-van den Hurk et al. (1985) Virology 14~:204-215.
Radiolabeled cells were harvested by scraping, washed with HBSS, and resuspended in modified RIPA buffer (50 ~ Tris hydrochloride, pH 8.0, 150 mM NaCl, 1~ sodium deoxycholate, 1~ Nonidet P-40, 0.1% SDS and 1 InM
phenylmethylsulfonyl fluoride). After incubation on ice for 15 min, the cell suspensions were sonicated then centrifuged at 75,000 x g for 1 h at 4C. The super-natants were collected, gI or gIII-specific monoclonal antibody ascites fluid were added to a final dilution of 1: 20, SDS was added to a final concentration of 0.2 to 0.5~, and the samples were incubated for 16 to 18 h at 4C on a rocking platform. Coated protein A-Sepharose (PAS) beads were prepared by swelling lyophilized PAS
beads in modified RIPA buffer at a concentration of 10 mg per ml for 1 h at 4C on a rocking platform then adding rabbit IgG anti-mouse IgG to a final concentration of 800 ~g per ml, and incubating for a further 16-18 h. After incubation, unbound rabbit IgG anti-mouse IgG was removed from the coated PAS beads by washing three times with modified RIPA buffer. Approximately 10 mg of coated PAS
beads were added to each mixture of radiolabeled cell lysate plus monoclonal antibody and the samples were incubated at 4C on a rocking platform. After 3-4 h, the samples were washed 4 times with modified RIPA buffer then resuspended in reducing sample buffer (62 rnM Tris hydrochloride, pH 6.8, 2~ SDS, 5~ 2-mercap~oethanol, 10 glycerol and 0.01~ bromophenol blue) and boiled for 4 min. Samples were separated by electrophoresis in 10 SDS-polyacrylamide gels and fluorographed.

III.A.7. AbCC
Transfected murine clones were seeded into 96-well round-bottomed plastic tissue culture plates at a RBNS06FO . WP .12 .: . : ': . :

~` , :~: . :
' -' - ' : ' ~ ~, ~' :' . ' 29310-20005.20 Client ID None PATENT

density of 2 x 103 cells per well and incubated at 37C
in growth medium containing 1.5 uCi per well of Na251CrO4 for 24 h. The plates were washecl 3 times and gI, or gIII-specific monoclonal antibodies were added at various dilutions in DMEM containing 2~ FBS and 1 ~g of actinomycin D per ml. The transformed cells, like all normal nucleated cells, are resistant to complement attack in the absence of metabolic inhibitors such as actinomycin D. After 2 h incubation at 37C, freshly thawed rabbit complement (Cedar Lane, Hornby, Ontario, Canada), at various dilutions, was added. Control wells for calculation of total releasable radiolabel received 3% Triton X-100 instead of complement. After 90 min incubation at 37C, 50~ of the supernatant fluid from each well was harvested, counted and the specific release was calculated as previously described. Misra et al.
~1982), supra.

III.A 8. Cytotoxic T Cell Cytotoxicity (CTCC) C3H/HeJ (H-2k) or Balb/c (H-2d) mice were im-munized intraperitoneally with approximately 108 PFU of BHV-1 at 8 and 11 weeks of age. Three weeks after the second immunization, the spleens were excised and cell suspensions prepared by gentle homogenization. The 25 suspensions were treated with 0.83~ ammonium chloride to -remove erythrocytes, then washed, counted, viability scored, and seeded into 6-well tissue culture plates at a concentration of approximately 2 x 1o6 cells per well in RPMI 1640 medium containing 10~ FBS, 25 mM HEPES and 5 x 10 5 M 2-mercaptoethanol. The cells were restimulated with 2 x 106 PFU of BHV-1 per well and incubated at 37C
in a humidified, 5~ CO2 atmosphere for 6 days.
L929 and 3T3 cells to be used as targets were suspended in RPMI medium and infected with BHV-1 or vaccinia virus at a multiplicity of infection of 5 for 1 RBNS06FO . WP .12 . - , . . .

: ~ ` ., :

29310-20005.20 Client ID None PATENT

h at 37C. Infected targets, uninfected controls, and transfected cells were then labeled with Na251CrO4 for 1 h at 37C. The labeled target cells were washed three times with RPMI medium containing 5~ FBS, 25 mM HEPES, and 5 x 10 5M 2-mercaptoethanol, then seeded into U-bottom microtiter plates at 104 cells per well.
Restimulated effector cells were washed, counted, viability scored and added to the plates containing radiolabeled targets at various effector to target cell ratios, with quadruplicate wells for each variable. The plates were then incubated for 7 h at 37C
in a 5~ CO2 atmosphere before supernatant fluids were harvested, counted and specific cytotoxicity values calculated as previously described. Lawman et al. (1980) 15 Infec. Immun. 30:451-461.

III.A.9. Immunizations with Transfected Cells and Antibody Titrations C3H/HeJ mice were immunized intraperitoneally 20 with 106-5 transfected cells suspended in 0.5 ml of HBSS, without adjuvant, at 6, 10 and 14 weeks of age. Pooled sera were obtained at 5, 8, 11 and 15 weeks of age from groups of 5 identically immunized mice. BHV-1-specific antibody levels were measured by virus neutralization and ELISA assays as described in Example I.

III.B. Results III.B.1. Construction of Plasmids (i) gI Constructions. The gene encoding BHV-1 gI was inserted into the eukaryotic expression vector pRSVcat in place of the cat gene such that the start codon of the gI gene was situated 100 base pairs (bp) downstream of the RSV promoter and 70 bp downstream of the transcriptional start site associated with this RBNS06FO . WP .12 ., . ~ .. .. . .
., : .- . - : - ~ . . . :-', ' ' :. ' ~ . `
- ,:

29310-20005.20 Client ID None PATENT

promoter to give pRSVgI (Figure 15A). Yamamoto et al.
(1980) Cell 22:787-797. These manipulations remo~ed the normal viral promoter upstream of the gI gene and placed the gene under the control of the Rous sarcoma virus enhancer/promoter unit. Approximately 480 bp lay between the stop codon and the SV40 based polyadenylation signals remaining in the expression vector after removal of the cat gene. A polyadenylation signal of BHV-l origin approximately 30 bp downstream of the gI gene stop co~on was retained in this construction, however, polyadenylation signal utilization was not examined for this or any of the plasmid constructions described below.
An LMTK cell line transfected with pRSVgI was designated RSVgI.
The gI gene was also inserted into the expres-sion vector pSV2neo in place of the neo gene such that the start codon of the gI gene was situated approximately 130 bp downstream of the SV40 early promoter and approximately 100 bp downstream of the transcriptional start site associated with this promoter to give pSV2gI
(Figure 15B). Fiers et al. (1978) Nature (London) 273:113-130. Following the gI gene stop codon were approximately 430 bp of non-coding BHV-l DNA, 170 bp of non-coding Tn5 DNA, the sequences encoding the SV40 small t antigen intron, and the SV40 polyadenylation signals.
Southern et al. (1982) J. Mol. App. Genetics 1:327 341.
An LMTK cell line transfected with pSV2gI was designated SV2gI.
(ii) gIII Constructions. The gIII gene was inserted into pRSVcat in place of the cat gene such that t~e gIII start codon was situated approximately 140 bp downstream of the RSV promoter and approximately 110 bp downstream of the transcriptional start site to give pRSVgIII (Figure 15C). Approximately 850 bp lay between the gIII stop codon and the vector associated SV40 RBNS06FO . WP .12 '` : ,, . :., ' . . - . , ' .:

29310-20005.20 Client ID None PATENT

polyadenylation signals. Whether this non-coding region contained polyadenylation signals of BHV-1 origin was not examined. An LMTK cell line transfected with pRSVgIII
was designated RSVgIII.
To place the gIII gene under the control of the SV40 enhancer/early promoter region, the gIII start codon was positioned approximately 170 bp downstream of the early promoter and approximately 140 bp downstrea~ of the transcriptional start site to give pSV2gIII (Figure 15D).
Following the gIII stop codon were approximately 800 bp of BHV-1 DNA, plus the Tn5 and SV40 sequences noted above for pSV2gI. An LMTK- cell line transfected with pSV2gIII
was designated SV2gIII.

III.B.2. Expression of Recombinant gI and gIII
Approximately 120 limit diluted clones from transfections of the four expression constructions described above, plus negative control clones derived from a transfection conducted with pSV2neo alone, were screened for expression of BHV-1 gI or gIII by ELISA and immunocytochemistry assays. The use of unfixed or methanol fixed and permeabilized cells in each assay revealed surface or surface plus intracellular glycoprotein expression, respectively.
ELISAs were used to compare the relative amount of surface and intracellular gI or gIII expression by clones derived from a single transfection, and, by clones derived from transfections with the different expression vectors. For 17 clones positive for gI expression, and 35 clones positive for gIII expression, a similar range and distribution of ELISA readings was obtained with either pRSV- or pSV2-based constructions.
Immunocytochemistry revealed that expression of gI was localized predominantly intracellularly in a perinuclear region which probably corresponds to the RBNSO 6FO . WP . 12 ..

"
,, 29310-20005.20 Client ID None PATENT

Golgi apparatus and/or rough endoplasmic reticulum of these cells as evidenced by the identical localization of wheat germ agglutinin. However, nuclear membrane and cell surface expression of gI were also visible. In addition, clones expressing gI exhibited a high degree of cell fusion, polykaryon formation, nucleus fusion and giant cell formation which was not apparent in clones expressing gIII or negative control clones. Expression of gIII was localized predominantly in the nuclear and plasma membranes although diffuse cytoplasmic staining was also evident. The subcellular distributions of recombinant gI and gIII are similar to those observed for these glycoproteins in BH~-1-infected bovine cells, although the perinuclear accumulation of gI in the transfected murine cells appears to be greater than that observed in infected bovine cells.

III.B.3. Comp~rison of Recombinant gI and qIII With Native gI and gIII
Radioimmunoprecipitation of gI from BHV-1-infected bovine cellg revealed three major protein bands of approximately 130,000 (130K), 75K and 55K
molecular weight which correspond, respectively, to the intact uncleaved glycoprotein and the two cleavable fragments which are linked by disulfide bonding in the mature non-denatured molecule. Only the latter two cleavage fragments were precipitated from two clones of murine cells transfected with gI expression plasmids, indicating that proteolytic cleavage of gI occurred to completion in these cells. In addi~ion, the larger of the two frayments produced in the transfected murine cells was slightly lower in MW than the equivalent fragment produced in infected bovine cells. Identical results were obtained with a number of other clones positive for gI expression.

R~NS06FO . WP .12 :
:

..
' , ~ ;. . 1 29310-20005.20 Client ID None PATENT

Radioimmunoprecipitation of gIII from BHV-1-infected bovine cells yielded two major bands of approximately 99K and 73K. These correspond, respectively, to the mature glycosylated gIII and its partially glycosylated precursor form. Only the former band was precipitated from clones of murine cells transfected with the gIII expression plasmids, suggesting that the precursor form(s) of gIII are more completely processed to mature molecules in the murine cells. As observed for gI, recombinant gIII had a slightly lower MW
compared to the mature form of gIII produced in infected bovine cells. These results were also verified by analysis of a number of other clones positive for gIII
expression.
Analysis of the proteins precipitated from cells treated with an N-linked glycosylation inhibitor, tunicamycin, was conducted to compare the N- and O-linked glycosylation patterns of the recombinant and infected cell glycoproteins. Radioimmunoprecipitation with gI-specific antibodies yielded a single band of approximately 105K MW from both infected bovine cells and gI transfected murine cell clones although additional partially glycosylated products of approximately 45-50K
MW also accumulated in the transfected cells. The 105K
MW band corresponds to the nonglycosylated, uncleaved form of gI which accumulates due to the dependence of gI
proteolytic cleavage on N-linked glycosylation and/or associated function(s) which are blocked by tunicamycin.
The identical MW of this band in both infected bovine cells and transfected murine cells indicates ~hat no O-linked oligosaccharides are added to gI in either cell type, and suggests that the MW differences described above for untreated cells may be due to differences in N-linked glycosylation.

RBNSO 6FO . WP . 12 : ' ' , ''`'' '"' ~ ' ' ~ ',' 29310-20005.20 Client ID None PATENT

Radioimmunoprecipitation of gIII from tunicamycin-treated, BHV-1-infected bovine cells yielded two bands of approximately 80K and 57K. These correspond to a glycosylated form of gIII, containing only O-linked oligosaccharides, and its nonglycosylated precursor.
Only a 70K band was precipitated from the tunicamycin-treated, gIII-transfected murine cell clones, suggesting that any precursor forms of gIII are rapidly processed in these cells, and that the amount of O-linked oligosaccharides added to gIII is lower compared to that added in infected bovine cells.
The antigenic structure of the recombinant gI
and gIII produced in the murine cell clones was analyzed with a panel of gI- and gIII-specific monoclonal antibod-ies, the majority of which have been mapped to differentepitopes on these glycoproteins. Relative antibody re-activity was assessed by ELISA and immunocytochemistry assays on both fixed and unfixed cells, and for selected monoclonal antibodies, by radioimmunoprecipitation and/or flow cytometry. The reactivity pattern of the entire monoclonal antibody panel was identical for the re-combinant and viral forms of gI and gIII, including two gI-specific, and four gIII-specific antibodies which do not recognize denatured forms of these glycoproteins.
These results suggest that the primary, secondary and/or tertiary structures of the recombinant glycoproteins, in the vicinity of the epitopes recognized by this panel of monoclonal antibodies, is indistinguishable from those of the glycoproteins produced in BHV-1-infected bovine cells.

III.B.4. AbCC and CTCC
The AbCC results indicate that gI and gIII are expressed on the surface of transfected murine cell clones at a level and in a manner which is recognized by RB~S06FO . WP .12 ,,' ` ~
-' , ` : : .

, . '` ` , :-29310-20005.20 Client ID None PATENT

complement-fixing gI- and gIII-specific monoclonal anti-bodies and which thereby renders the cells susceptible to attack by complement. The lower levels of lysis of cells expressing gI is primarily due to the higher spontaneous release of radioactive label from unstable fusing cells and polykaryons.
In CTCC assays using transfected murine cell clones expressing gI or gIII as targets, splenic lympho-cytes from mice immunized and restimulated with BHV-1 recognized and lysed histocompatible transfected cells expressing gI and gIII, as well as positive controls infected with BHV-1. A portion of this activity was non-specific natural killer cell-like cytotoxicity as evidenced by the lysis of vaccinia virus-infected targets and nonhistocompatible targets. However, the marked restriction of cytotoxicity which occurred when nonhistocompatible target cells were used provided proof of the involvement of cytotoxic, MHC-restricted, T
lymphocytes. The levels of lysis for pRSV-versus pSV2-based transfected cells does not correlate ~ith the comparable total expression of the recombinant glycoproteins as measured by radioimmunoprecipitation and ELISA and may, therefore, reflect quantitative and/or qualitative differences in the amount of processed antigen(s) which is produced by the different transfected cell lines and recognized by the cytotoxic effector cells in this assay.

III.~.5. Immunogen1city of Transfected Cells in Mice Histocompatible mice immunized with transfected cells in the absence of adjuvant produced detectable BHV-1-specific antibody after only one immunization.
Both ELISA and virus-neutralizing antibody levels were significantly boosted by secondary but not by tertiary immunization. The induction of comparable antibody ~B~S06FO . WP .12 :: ' ' . :`.................................. : "' :

,' ' :, , ~: . `, : . ~

29310-20005.20 Client ID None PATENT

levels with cells expressing gI or gIII under the control of different enhancer/promoter units corroborates the data above which suggests that the SV40 and RSV elements are quantitatively equivalent expression units for these glycoproteins in LMTX cells. The induction of significant levels of virus-neutralizing antibody supports the reactivity and cytotoxicity data which indicate that the recombinant glycoproteins are antigenically authentic.
IV

This example demonstrates the production of non-native BHV-l subunit antigens using a Baculovirus system.

IV.A. Materials and Methods IV.A.l. Cells. Viruses and Antibodies Madin Darby bovine kidney (MDBK) cells were cultured in Eagle's minimal essential medium (MEM; GIBCO
Laboratories, Grand Island, N.Y.) supplemented with 105 fetal bovine serum (GIBCO). S. fruqiperda (SF9) cells were grown and maintained in TNM-F~ medium (GIBCO) containing 10% fetal bovine serum as described by Summers and Smith tsummers, M.D., and Smith, G.E., "A manual of methods for baculovirus vectors and insect cell culture procedures'~ Texas ~gricultural Experiment Station bulletin no. 1555 (1987). Texas Agricultural Experiment Station, College Station, Tex.). Virus stocks of BHV-l strain Pa-2 were grown in MDBK cells as described in Example I. Virus stocks of the baculovirus AcNPV and recombinant vlruses were prepared in SF9 cells as described by Summers and Smith (supra). Monoclonal antibodies specific for gIV were developed and RBNSO 6FO . WP .12 :, . '' , ~ :' ` :
,. ' ' - ' ~ , ' , , . , ' ~
, ,: , , , 29310-20005.20 Client ID None PATENT

characterized by van Drunen Littel-van den Hurk et al.
(1987) Virology 160:465-472; and Hughes et al. (198a) Arch. Viol. 103:47-60. The gIV-specific monoclonal antibody mixture used for identification of recombinant gIV consisted of eguivalent amounts of 136 (epitope Ia), 9D6 (epitope Ib), 3E7 (epitope II), lOC2 (epitope IIIa), 4Cl (epitope IIIb), 2C8 (epitope IIIc), 3C1 (epitope IIId), and 3D9S (epitope IV).

IV.A.2. Insertion of BHV-1 Glycoproteins into the AcNPV
Transfer Vector The gIV glycoprotein gene was isolated from a subclone of pSD48 as a 1.3 kb MaeI fragment (Tikoo, S.K.
et al. (1990) J. Virol. 64:5132-5142, which was blunt end repaired and inserted into the plasmid pRSV cat (Fitzpatrick, D.R. et al. (1988) J. Virol. 62:4239-~248). The 1.3 kb BglII fragment was then subcloned into the BamHI site of the baculovirus transfer vector pVL941 (Luckow, V.A. and Summers, M.D. (1989) Virology 170:31-39). Plasmid DNA was prepared by alkaline lysis andcesium chloride gradient centrifugation by standard methods. After transformation of E. coli JM105, colonies appearing on LB agar containing 100 ~g of ampicillin per ml were inoculated into L broth con~aining ampicillin and incubated at 37C overnight with vigorous shaking. Small scale preparations of plasmid from each colony were prepared, and the presence of the gIV gene was confirmed by digestion with endonucleases AvaI and EcoRV. A single clone was identified containing the gIV gene in the desired orientation and designated pVLgIV. Clone pVLgIV
was inoculated into 500 ml. of L broth containing ampicillin; after 24 h at 37C, the plasmid was prepared by alkaline lysis and further purified by equilibrium centrifugation on CsCl.

RBNS06FO .WP .12 ` , . ., ~ : .

'` .:
f 29310-20005.20 Client ID None PATENT

A modified ~HV-1 gIV gene, as described in Example II.C.3, that produces a truncated form of gIV, was digested with BglII, the fragment isolated and subc].oned into the BacHI site of the baculovirus transfer vector pVL941. This construct was named pVLgIVt.
The gI glycoprotein gene contained in plasmid pgB complete, described in Example II.B.1, was digested with BglII and BamHI and inserted into the BamHI site of the baculovirus transfer vector pVL941.
The gIII glycoprotein gene contained in plasmid pll3R1 Bgl 3.0, as described in Example II.B.1, was transfered to the BamHI site of baculovirus transfer vector pVL941 as an EcoRI + BamHI subfragment. This construct was designated pVLgIII.
IV.A.3. Trans ection and Selection of Recombinant Viruses After two cycles of ethanol precipitation, purified plasmid was mixed with an equal amount of A.
californica viral DNA and used to transfect subconfluent monolayers of SF9 cells as outlined by Summers and Smith (supra). After incubation at 28C for 5 days, the supernatant was serially diluted and inoculated onto confluent monolayers of SF9 cells. After 1 h, an overlay consisting of TNM-FH medium containing 6~ fetal bovine serum and 1.5~ low-gelling-temperature agarose was added, and the plates were incubated at 28C Eor 5 days.
Recombinant baculoviruses were identified by plaque hybridization essentially as outlined by Summers and Smith (supra). The polyhedrin-negative recombinants were plaque purified three to four times on SF9 cells to remove contaminating wild-type baculoviruses.

RBNS06FO . WP .1~2 :` .

' ` , ' , ' ~ :
,. - : .' , ` ~: , ~

29310-2000S.20 Client ID None PAT~NT

IV.A.4. Preparation of Cell Lysates To analyze expression of recombinant gIV
confluent monolayers of SF9 cells on 35 mm petri dishes were infected with individual polyhedrin-negative recombinants at a multiplicity of infection of 5 and incubated for ~8 h at 28C. The cells were scraped into phosphate-buffered saline (PBS), pelleted at 150 x g for 1 min, and suspended in 50 ~l of RIPA buffer (0.02 M Tris hydrochloride ~pH 8.0], 0.15 M NaCl, 1~ sodium deoxycholate, 1~ Nonidet P-40, 10 mM EDTA, 10 mM
phenylmethylsulfonyl fluoride). The postnuclear supernatant was collected, combined with reducing electrophoresis sample buffer, and boiled for 2 min.
To determine approximate yields of recombinant gIV, SF9 cells in monolayers or suspension cultures were infected with recombinant virus at a multiplicity of infection of 1. The cells were harvested at various times postinfection, washed with PBS, and suspended in RIPA buffer at 107 cells per ml. Samples representing 5 x 104 to 2.5 x 105 cells were combined with reducing electrophoresis sample buffer and boiled for 2 min.
Equivalent samples from uninfected cells and/or cells infected with the parental virus were always included as controls.

IV.A.5. SDS Gel ElectroPhoresis Immunoblotting, and Enzyme-Li_ked Immunosorbent Assay (ELISA) SDS-polyacrylamide gel electrophoresis was performed in 8.5 or 10~ polyacrylamide discontinuous gels as previously described (van Drunen Littel-van den Hurk, S. et al. (1984) Virology 135:466-~79). Electrophoresis was carried out under reducing conditions. Protein bands were visualized by staining with Coomassie brilliant blue, and the stained gels were scanned at 595 nm with a RBNS06FO . WP .12 .

29310-20005.20 Client ID None PATENT

Helena Cliniscan II densitometer (Helena Laboratories, Mississauga, Ontario, Canada).
To identify recombinan~ gIV, produced by baculovirus, an immunoblot assay was perEormed as previously described (van Drunen Littel-van den Hurk, S.
et al. (1984) Virology 135:466-479). Briefly, after electrophoresis cell lysates were electrophoretically transferred to nitrocellulose sheets. then the instructions for use of the Bio-Rad (Mississauga, Ontario, Canada) immunoblot assay kit were followed.
Sandwich assays and indirect ELISAs were used to determine the yield of gIV in recombinant baculovirus-infected SF9 cells. In the sandwich assayj microtiter plates were coated with the immunoglobulin G (IgG) fraction of bovine hyperimmune serum as the captive antibody and then incubated with lysates from recombinant virus-infected and control cells or affinity-purified standard gIV. In the indirect assay, the cell lysates and glycoproteins were directly adsorbed to the microtiter plates. Mixtures of gIV-specific monoclonal antibodies, followed by horseradish peroxidase-conjugated goat anti-mouse IgG (Boehringer-Mannheim, Dorval, Quebec, Canada) were used for detection as previously described (van Drunen Littel-van den Hurk, S. et al. (1984) Virology 135:466-479). The reaction was visualized using 0.8 mg of 5-aminosalicyclic acid per ml and 0.006% H2O.

IV.A.6 Immunofluorescence and Flow Cytometry The expression of glycoprotein gIV in recombinant baculovirus-infected SF9 cells was determined at different times postinfection. Briefly, cells were washed in PBS, and cytospin smears were prepared and fixed in methanol. they were incubated for 30 min at 37C with a l::L00 dilution o~ a gIV-specific monoclonal antibody mixture and washed in PBS and double-distilled RBNS06FO . WP .12 ., . ;~ , ' , - ~ ~ , ' ' ::
.- . :

:

29310-20005.20 Client ID None PATENT

water. Then the cells were stained with fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG
(Boehringer-Mannheim) for 30 min at 37C and washed again before being mounted in PBS-glycerol for examination.
For surface staining and flow cytometric analysis, cells were suspended in PBS containing 0.2~ gelatin and 0.03~
NaN3 (PBSG) at 4 x 107 cells per ml. They were plated in microtiter plates at 2 x 1o6 cells per well and incubated with serial dilutions of monoclonal antibody mixtures for 30 min on ice. Subsequently, they were washed in PBSG
and then incubated with ~luorescein isothiocyanate-conjugated rabbit anti-mouse IgG (Becton and Dickenson, MIssissauga, Ontario, Canada) for 30 min at 4C. After the cells were washed, they were fixed in 2~ formaldehyde and analyzed with an EPICS CS flow cytometer (Coulter Electronics Ltd., Hialeah, Fla.) as described (Campos, M.
et al. (1989) Cell. Immunol. 120:259-269). The percentage of positive cells was calculated by using the immuno-program (Coulter Electronics Ltd.; MDAPS system) for the analysis of immunofluorescence histograms.

IV.A.7. Partial and Affinity Purification of Recombinant Proteins To obtain a standard glycoprotein for the quantitative ELISA, glycoprotein gIV was purified by immunoadsorbant chromatography from recombinant baculovirus-infected SF9 cells as previously described (van Drunen Littel-van den Hurk, S., and Babiuk, L.A.
(1985) Virology 144:204-215). Partially purified membrane preparations were made from recombinant baculovirus-infected SF9 cells to immunize cattle.
Briefly, infected cells were harvested at 48 to 72 h postinfection, when maximal production of recombinant gIV
was achieved. the cells were collected by centrifugation, washed with PBS and suspended in MEM

RBNSO 6FO . WP .12 `' - ~.

29310-20005.20 Client ID None PATENT

containing lO mM phenylmethylsulfonyl fluoride and 10 mM
EDTA at 107 cells per ml. Subsequently, they were disrupted by treatment for 15 s with a polytron homogenizer (Brinkmann Instruments, Rexdale, Ontario, Canada). The insoluble material was collected by centrifugation for 8 min at 1,800 x g and suspended in MEM containing 10 mM phenylmethylsulfonyl fluoride and 10 mM EDTA.

IV.A.8._ Immunization of Cattle Groups of eight animals each were immunized with crude cell lysate, a membrane preparation, or affinity-purified glycoprotein from recombinant baculovirus-infected SF9 cells expressing gIV. All preparations were diluted to a concentration of 100 ~g of gIV per dose and mixed with Avridine as previously described (Babiuk, L.A. et al. (1987) Virology 159:57 66) or with Emulsigen PLUS at a ratio of 7:3 (vol/vol), as outlined by the manufacturer (~VP Laboratories, Ralston, Nebr.). Control groups were immunized with affinity-purified authentic gIV, a commercially available killed BHV-1 vaccine, or placebo containing AcNPV-infected SF9 cells. The animals were injected intramuscularly, and they received a booster immunization 21 days later. Blood samples were taken from animals at the times of immunization and 2 weeks after the second immunization for assessment of antibody responses.

IV.A.9. Antibody Responses to Vaccination The antibody responses to recombinant gIV in the vaccinated animals were determined by ELISA with affinity-purified authentic gIV from BHV-1 infected MDBK
cells as the antigen, essentially as previously described (Babiuk, L.A. et al. (1987) Virology 159:57-66); van Drunen Littel-van den Hurk, S. et al. (1984) Virology RBNSO 6FO . WP .12 '' ~' ~' .;.
;' 29310-20005.20 Client ID None PATENT

135:466-479). Affinity-purified horseradish peroxidase-conjugated rabbit anti-bovine IgG (Zymed, Missauga, Ontario, Canada) was used at a dilution of 1:3,000 for detection.
The neutralization titers of the bovine sera were determined as previously described (Babiuk, L.A. et al. (1975) Infect. Immun. 12:958 963). The titer was expressed as the reciprocal of the highest dilution of antibody that caused a 50~ reduction of plaques relative to the virus control.
The epitope specificities of the antibody responses to recombinant gIV were determined in a competitive antibody binding assay, which is based on the ELISA modified as previously described (van Drunen Littel-van den Hurk, S. et al. (1990) Vaccine 8:368-36);
and van Drunen LIttel-van den Hurk, S. et al. (1985) Virology 144:216-227). The percentage of competition was calculated by using the formula [100 x (A - B)/A], where A is the absorbance in absence of competitor antibody and B is the absorbance in the presence of competitor monospecific antibody; this is a modification of the formula described by Kimura-Kuroda, J. and Yasui, K., J.
Virol. 45:124-132.

IV.B. Results IV.B.I. Identification of Recombinant gIV Glycoprotein in Infected SF9 Cells Several baculovirus recombinants containing the gIV gene insert were initially identified and tested for their ability to produce BHV-l glycoprotein gIV after infection of SF9 cells. All of the gIV recombinants produced a polypeptide with an apparent molecular mass of 63 kDa which was absent from uninfected cells and cells infected with the parental baculovirus. To confirm the RBNS06FO .WP .12 : ~ :

.

':

29310-20005.20 Client ID None PATENT

identify of this glycoprotein, immunoblot analysis was performed. Recombinant baculovirus-infected SF9 cells and BHV-1-infected MDBK cells were harvested at 4~ h postinfection, and total proteins were separated and transferred electrophoretically to nitrocellulose. A
gIV-specific monoclonal antibody mixture recognized authentic gIV (71 kDa) in ~HV-1-infected MDBK cells and a polypeptide with an apparent molecular mass of 63 kDa in recombinant baculovirus-infected SF9 cells. This suggests that the recombinant gIV is equivalent to the 63-kDa partially glycosylated form of authentic gIV (van Drunen Littel-van den Hurk and ~abiuk, L.A., J. Virol.
59:401-410). In addition to the 63 kDa species, four bands of lower apparent molecular mass were observed in the immunoblot of recombinant gIV. These bands, which were also present in a preparation of pure authentic gIV, may be due to proteolytic cleavage or incomplete processing of the glycoprotein. No reaction was observed between the gIV-specific monoclonal antibodies and SF9 cells infected with the parental baculovirus.

IV.B.2. Cellular Localization of the Recombinant gIV
Glycoprotein To determine the intracellular distribution of the recombinant gIV glycoprotein, indirect and surface immunofluorescence tests were performed on recombinant baculovirus-infected SF9 cells. At ~8 h after infection, the gIV glycoprotein was primarily localized in the cytoplasmic membranes of the perinuclear region of the insect cells. Surface fluorescence was observed on unfixed cells, indicating that the recombinant glycoprotein i9 transported to the extracellular surface of the plasma membrane of the insect cells.

RBNS06FO . WP .12 ~: .

293:L0-20005.20 Client ID None PATENT

IV.B.3. Kinetics and Levels of Expression of the Recombinant gIV Glycoprotein To analyze the kinetic~ and the efficiency of infection with the recombinant baculovirus and expression of the gIV glycoprotein, SF9 cells were grown in suspension cultures and infected with the recombinant baculovirus at a multiplicit~ of infection of 1. In this experiment, the viability of the cells, percentage of infected cells, and yield of gIV were determined. Flow cytometric analysis showed an increase in percentage of infected cells as well as total protein yield over time.
The percentage of infected cells reached peak levels of 80~ at 48 h after infection, when the viability of the cells was down to 30%. The viability of the cells was too low for flow cytometric analysis beyond this time point. Analysis by ELISA demonstrated that up to 85 ~g of gIV was produced per 2.5 x 1o6 cells. This was confirmed by SDS-polyacrylamide gel electrophoretic analysis of the proteins produced during the first 72 h postinfection. The gel was scanned; polyhedrin made up 36~ of the total protein, whereas gIV made up 18~. The total protein concentration of recombinant virus- and AcNPV-infected cells was determined by the Bradford test to be about 500 ~g per 2.5 x 1o6 cells. This corresponds to about 180 ~g of polyhedrin and 90 ~g of gIV, demonstrating the feasibility of growing the recombinant baculovirus on a large scale and yet obtaining good yields of the glycoprotein.
IV.B.4. Antigenic Pro~erties of gIV E~ressed by the Recombinant Baculovlrus The antigenic properties of recombinant gIV
were evaluated by using a gIV-specific panel of monoclonal antibodies. The epitopes recognized by these RBNS06FO . WP .12 . , , ' ~ ` ,~

29310-20005.20 Client ID None PATENT

monoclonal antibodies have been identified and characterized previously (Hughes, G. et al., Arch. Viol.
103:~7-60). Reactivity of all of these monoclonal antibodies in an E~ISA indicated that all of the epitopes identified on the authentic glycoprotein are also present on recombinant gIV, although some of the conformation-dependent epitopes (IIIb, IIIc, IIId ~Hughes, G., et al., supra]) were recognized slightly better on authentic gIV
than on recombinant gIV. Since it has been shown that these epitopes are not directly carbohydrate dependent (van Drunen Littel-van den Hurk, S. et al. (1990) J. Gen.
Virol. 71:2053-2063), this suggests that incomplete glycosylation might lead to some conformation changes in the gIV molecule. In contrast, the continuous epitope IV
seemed to be more reactive on recombinant gIV.

IV.B.5. Immunogenic Properties of gIV Produced by the Recombinant Baculovirus The immunogenicity of recombinant gIV was studied by immunizing cattle with crude, partially purified, or affinity-purified glycoprotein from recombinant baculovirus-infected SF9 cells, as described above. This experiment showed that two immunizations of affinity-purified glycoprotein or partially purified membrane preparation in Emulsigen PLUS elicit antibodies that are reactive with authentic gIV and able to neutralize infectivity of BHV-1 i vitro. The crude cell lysate, however, induced antibodies that were reactive with authentic gIV but that neutralized poorly. Since the partially purified membrane preparation was as immunogenic as the affinity-purified recombinant gIV, whereas the crude cell lysate was not, the membrane preparation was used for further studies. A second experiment was designed to compare the efficacies of two different adjuvants and to compare the immunogenicity of ~BNS06FO . WP .12 .

:
.

: .
` i ,:

29310-20005.20 Client ID None PATENT

recombinant gIV with that of an experimental vaccine consisting of authentic gIV (Bab:Luk, L.A. et al. (1987) Virology 159:57-66) and a commercially available and widely used killed HBV-1 vaccine (Figure 16). Two immunizations with 100 ~g of recombinant gIV induced high neutralizing antibody titers, three- to six-fold higher than those induced by the killed virus vaccine. this experiment also showed that Avridine is superior to Emulsigen PLUS, resulting in twofold-higher E~ISA and neutralizing antibody titers (Figures 16A and 16B). A
significant difference was observed between the immune responses induced by authentic and recombinant gIV.
Authentic gIV induced 4-fold-higher ELISA titers and 20-fold higher neutralizing antibody titers. this difference may be due to alterations in some of the conformation-dependent neutralizing epitopes on recombinant gIV.

IV.B.6. Epitope Specificity of the Immune Response to the Glycoprotein Vaccines To determine whether the lower neutralizing antibody response to recombinant gIV was due to impaired recognition o~ one or more of the neutralizing epitopes, the sera from the immunized animals were tested with respect to epitope specificity. All epitopes on gIV were recognized by animals immunized with authentic gIV;
blocking varied between 84 and 30~ (Figure 16C). These values are in good agreement with previously reported values between 85 and 50~ (van Drunen Littel-van den Hurk, S. et al. (1990) Vaccine 8:358-368). However, two of the neutralizing epitopes on gIV, Ia and Ib, were poorly recognized by animals vaccinated with recombinant gIV. This may explain the difference in neutralizing antibody titers. These animals d.id show a reaction to all of the other epitopes, although the reaction was not RBNSO 6FO . WP .12 , ,- - - .
- ' : ., . :~

, , - , ', , .i 29310-20005.20 Client ID None PATENT

as strong as those of animals immunized with authentic gIV. The reactivity of the sera was to a certain extent also dependent upon the choice of adjuvant; Avridine was slightly superior. Calves immunized with killed BHV-1 vaccine only reacted to epitope 3E7.

This example demonstrates the production of non-native BHV-1 subunit antigens in E. coli vectors.

V.A. Cloning and Expression of the BHV-1 gI Gene in E.
co1i A BHV-1 genome library of BHV-1 strain Cooper as represented in 12 HindIII fragments cloned in to pBR322, was screened according to the methods of Southern, using probes corresponding to HSV-1 gB and the pseudorabies virus (PRV) gB gene counterpart. A single clone, pSD106, was found to bind to the probe3.
In order to specify the actual coding sequences of the BHV-1 gI gene, a detailed restriction map was constructed for pSD106. The application of the techniques of Southern using separate probes specific for the HSV-1 gB amino and carboxy-termini, located the BHV-1 gI gene within a KpnI - SalI sub-fragment of pSD106 (pSD106 KpnI-SalI; Figure 17).
It is not expected that foreign viral proteins produced in E. coli would be folded into a configuration that mimics the protein in the native virus particle.
Therefore, the most active immunogen obtained from bacterially expressed genes is likely to be composed of a contiguous stretch of amino acids rather than one which requires the positioning of two or more contiguous sequences of amino acids (i.e., tertiary structure). An additional l.imitation is that E. coli will not process RBNS06FO .WP .12 . . ~
;, ': ` , . ,',". ' :

29310-20005.20 Client ID None PATENT

pre gI to gIb + gIc. Thus, it was hypothesized that the optimal formulation of bacterially expressed gI would be composed of gIb and gIc, expressed individually and then utilized either separately or in combination.
To construct a clone expressing the amino terminus of mature gIb + gIc, the pSD106 KpnI - SalI
fragment was cut with ApaI and the lengths of the ApaI
fragments randomized by treatment with Bal31 exonuclease.
Any asymmetric fragment\ends produced by imprecise Bal31 activity were blunted by Klenow fill-in reactions. The ApaI digested plasmid was then cut with XmaI and the population of fragments carrying sequences encoding the amino terminus of gIb were isolated from LMP agarose gels as a 600-520 bp smear. This fragment sub-population was then ligated to the HpaI - XmaI sites of polink 26.
Polink 26 was a modified form of pBR328 and contained a synthetic oligonucleotide inserted into the EcoRI and SalI sites. The oligonucleotide contained restriction enzyme sites in the following order: EcoRI, XbaI, BglII, BalI, HpaI, ClaI, HindIII, KpnI, BamHI, SmaI, SphI, SacI, XhoI, SalI.
Inserts from the clone bank of the gIb ~ gIc amino terminus were isolated by BglII and SmaI digestion of sBHB5' and transferred to the BglII plus SmaI sites of the E. coli expression vector pHK414. The resulting clone was named pRed30. To complete the construction of the gpll gene, SmaG was isolated as a 775 bp XmaI
fragment from pSdlO6 XpnI - SalI and was ligated to the XmaI site of p~ed30 to produce pgpll:~gal. This plasmid was transformed into the E. coli strain NF1829 produced a gpll:~-galactosidase fusion protein of approximately 175k. An unfused gIb peptide was made by the "gpll complete" clone. "pgpll complete" (Figure 18) was constructed by transferring the 13~0 bp BglII - BamHI
fragment from pgpll:~gal to the E. coli expression RBNS06FO .WP . 12 . `~ ~ . . . : . ~ , . , 293~0-20005.20 Client ID None PATENT

plasmid pGH346. The 1340 bp Eragment carries the entire gIb coding sequence plus DNA encoding the first eight amino acids of gIc. In NF1829, ~pgpll complete" produces a 60k protein which specifically reacts to BHV-1 gIc polyclonal sera and gIb specific monoclonal antibodies.

V.B. Cloning and Expression of BHV-1 qIII gene in E.
coli The BHV-1 genomic library was screened by the techniques of Southern using probes specific for the coding sequence of the HSV-1 gC and the PRV gC homolog (PRV gI). One of the HindIII clones, designated pSD113 (Figure 17), hybridized to both the probes. A
restriction endonuclease map of the pSD113 plasmid was prepared in order to locate the region within the HindIII
fragment which specifically encoded the BHV-1 gIII gene.
By using a probe specific for the PRV gC gene homolog, the BHV-1 gIII gene was located within an approximately 2500 bp EcoRI - BglII subfragment of pSD113.
An E. coli clone expressing the carboxy-terminal two-thirds of the BHV-1 gIII gene was made in the following way. The pSD113 EcoRI - BgII subfragment of pSD113 was digested with XmaI and inserted into the XmaI site of the plasmid pJS413 to form pBHC'. The pSD113 EcoRI - BglII subfragment of pSD113 was digested with PvuI and the PvuI asymmetric ends were treated with Klenow enzyme to blunt them. The PvuI digested plasmid was then cut with SacI, and the 1600 bp PvuI - SacI
fragment containing the carboxy-terminus of the gIII was purified from LMP agarose gels. This fragment was ligated to SmaI plus SacI sites of plasmid ptac413 to produce pll3Pv~l/413. The extraneous sequences 3' to the stop codon were removed by replacing the 900 bp AbaI -SacI fragment from pll3Pvu/413 with the 2220 bp AbaI -SacI fragment from BHC3'. The new plasmid "pll3 Pvu end"

RBNS06FO . WP .12 : :

: ' ",' ' . : ' :: :
:.................................... . , : ~
: ~ : : .. . ,~- . :`: ', : ~
.
.

29310-20005.20 Client ID None PATENT

carried 900 bp of BHV-1 gIII gene carboxy-terminus in frame to the reconstituted ~-galactosidase gene. The E.
coli strain NF1829 was transformed with this plasmid.
Upon induction with lactose, these cells produced approximately 5~ of the total protein as a gIII
related protein. The fusion product was collected as aggregates and solubilized in 10 mMol urea, pH 9.O. The solubilized protein was dialyzecl against 10 mMol triethylamine, pH 9.0 to remove urea and then concentrated by Amicon filtration to a final concentration of 2 mgs/ml of BXV-1 protein. The concentrated gIII fusion protein was formulated with Freunds' Complete Adjuvant and injected intramuscularly to rabbits in 1 mg doses. The antisera raised in these rabbits was used to immunoprecipitate BHV-1 infected cell extract and was found to specifically react with the gIII
glycoprotein.
In an attempt to express the full-length BHV-1 gIII gene in E. coli, the expressor clone "113Pvu end"
was extended to include all gIII coding sequences up to the NcoI site ("gIII complete~). This full-length clone failed to produce significant amounts of gIII protein.
The simple removal of the signal sequence and/or addition of preferred E. coli codons upstream of the gIII
sequences failed to improve expression. In order to produce the largest E. coli gIII expressor clone possible, and to avoid the apparent problem in expressing the amino terminal gene sequences, a library of gIII
clones was generated with randomized amino termini. The E. coli plasmid "gIII complete", which does not express significant amounts of gIII protein, was digested with NcoI and then treated with Bal31 for varying lengths of time. NcoI cut at the ATG of the gIII gene and 3al31 treatment removed nucleotides starting from the NcoI cut ends to varying extents. The population of random sized RBNS06FO . WP .12 ..

-29310-20005.20 Client ID None PATENT

plasmids were treated with Klenow enzyme to blunt asymmetric ends and were then digested with BamHI to excise the BHV-1 gIII insert. The population of NcoI -Bal31 - BamHI fragments ranging in size from 1530 bp to 1250 bp were isolated from ~MP agarose and ligated to the SmaI - BamHI sites of p~S413. E. coli NF1829 was transformed with this ligation mi.xture and plated to MacKonkey's Agar. Putative expressor clones were picked as red colonies. The positive colonies were then tested for protein production by lactose induction and protein analysis by SDS-PAGE. Three clones were found to express gIII as a ~-galactosidase fusion protein. The clones were found to differ in the amount of amino terminal sequence removed by the Bal31 treatment: losing 150, 250, and 350 bp, respectively. The gIII gene inserts were excised by BglII - BamHI digestion of the Bal31 expressor plasmids and then purified from LMP agarose gels. Each gIII carrying fragment was then ligated into the BglII - BamHI sites of the E. coll expressor plasmid GH435. pGH435 carries stop codons in each of the three possible reading frames immediately 3~ to the BamHI
insertion site. Therefore, expression of any insert at the BglII and BamHI sites would generate a nonfused peptide. The largest Bal31 clone, called pB~C150~
(Figure 19), which had a deletion of approximately 150 bp at the amino terminus of gIII, makes a peptide of approximately 53K upon lactose induction. This plasmid is carried in the E. coli strain W3110F'Iq.

V.C. Expression of Full-Length Mature BHV-1 qIV in E.
coli The BHV-1 genomic library clone pSD98 (Figure 17) was identified as carrying the bulk of the amino-terminal half of gIV + signal sequence, in addition to several other putative BHV-1 genes. Restriction enzyme RBN506F0 . WP .12 .:
:: ~, ~ ` ' ~ -~ : , ,: : ... : :

29310-20005.20 Client ID None PATENT

mapping of pSD98 mapped the gIV protein sequences plU9 signal sequence to within a XmalI - XhoI fragment of the plasmid. The pSD98 was digested with XmaI and XhoI, the fragment isolated and inserted into the ~lasmid polink 26 to produce p98XmaI - XhoI.
The construction of the gIV gene containing expression vector is depicted in Figure 20. The signal sequence does not appear in the mature gIV protein and does not contribute to immunogenicity of the glycoprotein. Therefore, the signal sequence was removed by making a synthetic oligonucleotide corresponding to the coding sequence of the first amino acid of the mature BHV-1 g~V gene (i.e., Leu) and extending to the SalI site 88 bp downstream from the start (ATG) of the gene (see Figure 7). An engineered HindIII asymmetric overhang was added immediately 5' to the Leu codon and a XmaI
asymmetric end was added i~nediately 3' to the SalI site (see Figure 20). The HindIII and XmaI overhangs permitted ligation of the oligonucleotide into the HindIII plus XmaI sites of the E. coli expression vector pHK414. The resultant plasmid was called BXDsyn43 and is carried in the E. coli strain MC1066.
The amino-terminus of the gIV clone BHDsyn43 was extended by ligating the 590 bp BamHI - SalI fragment ~rom p98Xma-XhoI to the SalI plus BamHI sites of the BHDsyn43. This ligation produced pBXD5' and carries the first 620 bps of the coding sequence for mature BHV-1 gIV. The pBHD5' was also maintained in the E. coli strain MC106.
An E. coli clone expressing full length mature BHV-1 gIV was made by first transferring the gIV insert from pBHD5' carried in a 630 bp BglII - BamHI fragment, to the BglII - BamHI sites of the E. coli expression plasmid GH432. The carboxy terminal half of the gIV gene was then added by ligating the 640 bp XmaI fragment from RBNS06FO .WP .12 :

- . ; .

29310-20005.20 Client ID None PATENT

pSD98 to the XmaI site in the new construction BHD5'/432.
The plasmid pSD98 was part of the original BHV-1 genomic library BHV-1 strain Cooper (Figure 17). The library takes the form of 12 HindIII clones of the viral genome inserted into the pBR322. Plasm:id pSD98 was identified as part of the gIV gene partially by its location in the "S" region of the BHV-1 genome, that corresponds to the location of the gD of other herpesviruses, e.g., HSV-1 and 2, PRV and EHV-1, and reactivity in Southern blots using a probe corresponding to the PRV gIV gene homologue.
The final BHV-1 gIV E. coli expressive plasmid is called pBHDsib (Figure 21) and was transformed in the E. coli strain W31104'Iq. Upon induction with lactose t2~ final concentration), pBHDsib made a 58K protein which represented approximately 10~ of the total protein produced by the clone. In a western blot assay, the 58K
protein reacted specifically with anti-BHV-1 hyperimmune serum and the BHV-1 gIV specific monoclonal antibody 3D9.
An aggregate preparation from pBHDsib was solubilized in 50 mMol ~-mercaptoethanol, 0.5% SDS pH
8Ø Doses containing 150 ~g of the 58K solubilized protein were prepared in Freunds~ Complete Adjuvant and administered to rabbits by intramuscular injection. Sera raised in these animals reacted specifically with a glycoprotein from BHV-1 infected cell extracts indistinguishable from gIV. When assessed for BHV-1 virus neutralizing activity i vitro, the rabbit sera was found to have a plaque reduction titre of 1:128.
V.D. Purification_of Recombinant BHV-1 Glycoprotelns E. coli W3110 transfected with pB~sib was cultured in L broth supplemented with ampicillin (50 ~g/ml). Late log growth phase cultures were induced with RBNS06FO . WP .12 , 29310-20005.20 Client ID None PATENT

either 2~ lactose or 2 mM IPTG. Five hours after induction, the cultures were harvested, the cells pelleted by centrifugation (2000g for 20 min) and then mechanically disrupted. The agg:regates were subsequently dispersed by treatment with 6M GuHCl and then dialyzed to reduce the GuHCl concentration to 2M.
The other BH~-1 glycop:roteins expressed in E.
coli are similarly purified.

VI

The following example illustrates the production of non-native BHV-1 subunit antigens in recombinant adenovirus vectors.
VI.A. Expression of BHV-1 gIV Using Adenovirus Vectors In one form, this expression system is based on human adenovirus serotype 5. The E3 region of the virus has been deleted to facilitate the accommodation of large gene inserts into the viral genome. When 293 cells (h~Iman kidney cells) are transformed with human adenovirus type 5 DNA, the cell line expresses the viral E1 protein constitutively. As a result, the combination of vectors based on human adenovirus type 5 and 293 cells form an ideal expression system.
A transfer vector, pAdBM5 (Figure 22), was developed in order to insert foreign gene sequences into human adenovirus serotype 5. The vector contains the adenovirus to major late promoter (Ad2MLP), enhancer sequences, and polyadenylation sequence, flanked by the adenovirus serotype 5 E1 flanking sequences. A unique BamHI site is located downstream of the M~P and is used for the insert:ion of foreign genes.
For the expression of either full-length BHV-1 gIV or truncated BHV-1 gIV, the appropriate gene was RBNS06FO . WP .12 - , ~ ' , ' ;

:

29310-20005.20 Client ID None PATENT

digested with MaeI and inserted into the dephosphorylated BamHI site of the pAdBM5. Figure 23 depicts pAdBM5.gIV, the adenovirus vector including the gene encoding for full-length gIV. The plasmid vector DNA was digested with ClaI, mixed with purified human adenovirus serotype 5 DNA and was used to transfect 293 cells using the calcium phosphate technique. The transfected cells were plated out and incubated at 37C until a cytopathic effect developed. Supernatant from these cultures was then removed and used to reinfect 293 cells. Once the cytopathic effect had developed, the cellular DNA
infected with virus was filled to hybridized, recombinant virions expressing BHV-1 gIV were identified, selected and then further purified by plaque assay.
VI.B. Purification of Recombinantly Expressed BHV-1 qIV
293 cells were cultured in MEM containing 10~
fetal bovine serum and supplemented with lX vitamins and minerals. Confluent monolayers were infected with the recombinant adenovirus: BHV-1 gIV virus, ~t a multiplicity of 0.1. 24 hours after infection or at the appearance of total cytopathic effect, the recombinant gIV was harvested.
For full-length gIV, the cells were scraped from the surface of the culture flasks into the growth media, which was then centrifuged (1000 g for 20 min) and the cell pellet collected. The cells were disrupted with detergent and further processed as previously described.
Truncated gIV was collected by harvesting the media from the culture flasks. Cell debris was removed by centrifugation at 1000g for 20 min. The clarified media was frozen at -70C until processing. The truncated gIV was purified by affinity chromatography through BHV-1 gIV specific columns, as has been described previously.

RBNS06FO .WP .12 .
' ..

.

29310-20005.20 Client ID None PATENT

VII

This example illustrates the efficacy o~
recombinantly produced BH~-1 subunit antigens.

VII.A. Materials and Methods VII.A.1. Cells and Viruses E. coli cells were cultured in L Broth. Madin Darby bovine kidney cells (MDBK) cells, BSC-1 cells, and 293 cells were cultured in Eagle~s minimal essential medium (MEM; GIBCO laboratories, Grand Island, N.Y., USA), supplemented with 10~ fetal bovine serum (F~S;
GIBCO). Spodoptera frugiperda (SF9) cells were grown and maintained in TNM-FH medium (GIBCO) containing 10~ FBS.
Strains P8-2 and 108 of BHV-1 were propagated in MDBK
cells as described previously (Babiuk et al. (1975) Infect.Immun. 12:958). Virus recovered from nasal swabs was quantified by pla~ue titration on MDBX cells in microtiter plates with an antibody overlay as previously described (Rouse et al. (1974) J.Immunol. 113:1391).
Vaccinia virus (WR strain) and recombinant vaccinia virus were propagated in BSC-1 cells as described in Example II. Human adenovirus type-5 and recombinant adenovirus were grown in 293 cells as described in Example VI.
Virus stocks of the baculovirus AcNPV and recombinant virus were prepared in SF9 cells as described by Summers and Smith (Summers et al., "A manual of methods for baculovirus vectors and insect cell culture procedures.
Texas Agricultural Experiment Station Research bulletin no. 1987, 1555, Texas Agricultural Experiment Station, College Station, Tex).

RBNS 0 6FO . WP .12 , .; ` ,: , `

, . . . .
' , ' ' ', 29310-20005.20 Client ID None PATENT

VII.A.2. Recombinant Expression of gIV
BHV-1 gIV was recombinantly expressed in E. coli, SF9 cells, adenovirus and vaccinia virus, as explained in the above examples.

VII.A.3. Preparation of Immunoaclsorbent Columns The IgG fraction of the gIV-specific monoclonal antibody 3D9S was prepared from ascites fluid, using a protein A-Sepharose CL-4B (Pharmacia, Montreal, Quebec, Canada) column. The purified IgG was dialyzed thoroughly against 0.1 M HEPES, pH 7.5 and linked to activated Affigel-10 (BioRad Laboratories, Mississauga, Ontario, Canada) at 5 mg protein per ml gel according to the manufacturer's instructions. An immunoadsorbent column was packed for each of four different gIV species.

VII.A.4. Purification of Glycoproteins Glycoprotein gIV was puri~ied from BHV-1 (strain P8-2) infected MDBK cells, recombinant AcNPV
infected SF9 cells, recombinant adenovirus infected 293 cells or recombinant vaccinia virus infected BSC-1 cells.
Cell lysates were prepared from the virus infected cells, essentially as described previously (Van Drunen Littel-van den Hurk et al. (1985) Virology 144:204-215).
Briefly, the cells were harvested, centrifuged at 1000 rpm and resuspended in 10 mM Tris-hydrochloride, 150 mM
NaCl, pH 7.5 containing 1~ Nonidet P40 (NP~0) and 1~
sodium deoxycholate. After the cell lysates had cycled three times through the respective gIV-specific monoclonal antibody columns, the columns were washed with one volume of sample application buffer and two volumes of wash buffer (10 mM Tris-hydrochloride, 500mM MaCl, 0.1~ NP40, pH 7.5). Specifically bound antigen was 35 eluted with 50 mM diethylamine, pH 11.5, immediately RBNS O 6 PO . WP . 12 - , ,,, ~ ... ...

, . : . . .;:
- : ~ , 29310-20005.20 Client ID None PATENT

neutralized with 1 M Tris-hydrochloride, pH 7, and concentrated on an Amicon YM30 membrane. The columns were re-equilibrated in sample application buffer for re-use or stored in phosphate-buffered saline (PBS), containing 0.02% sodium azide. The protein content was determined with the BioRad protein determination kit.
The purity was assessed by polyacrylamide gel electrophoresis alone and in combination with western blotting. Finally, the purified proteins were applied to appropriate cells to test for residual input virus.

VII.A.5. Polyacrylamide Gel ElectrophoresiS
Sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAG~) was carried out in 10%
discontinuous gels under reducing conditions as described previously (Laemmli, U.K. (1970) Nature 227:680-685).

VII.A.6. Immunization Groups of eight calves each were immunized intramuscularly with 25 ug of purified gIV, produced by BHV-1, baculovirus, adenovirus or vaccinia virus, or 100 ug of gIV produced in ~. coli. The glycoproteins were combined with the adjuvant Avridine as described previously (Babiuk et al. (1987) Virology 159:57-66). A
control group was vaccinated with Avridine only. Twenty-one days later the animals were boosted and then challenged with BHV-1 fourteen days after the booster immunization. Blood samples were taken from the animals at the time of the first immunization, booster immunization, and challenge, as well as ten days after challenge for assessment of antibody responses.

VII.A.7. Experimental Challenqe Fourteen days after the second immunization, animals were transported into an isolation pen and RB~IS06FO . WP .12 '~
' 293~.0-20005.20 Client ID None PATENT

examined clinically. Their weights and rectal temperatures were determined and recorded. ~lood samples and nasal swabs were collected to establish baseline values. The calves were then inclividually exposed to an S aerosol of 107 pfu per ml of BHV-1 strain 108, which was generated by a DeVilbis Nebulizer, model 65 (DeVilbis, Barrie, Ontario, Canada). The duration of the treatment was 4 min per calf.

VII.A.8. Clinical Evaluation - The clinical evaluations were performed at the same time each day by two independent investigators who were uninformed about the specific treatments of the individual animals. The parameters evaluated included depression, appetite, fever, conjunctivitis, rhinitis, mouth-breathing and tracheitis. In each case, a score of 0 was assigned to healthy animals. Clinical scores of 1-4 were assigned to sick animals as follows: 4, severe;
3, marked; 2, moderate; 1, mild. Temperatures were taken every day and nasal swabs were collected every other day and processed the same day. Blood samples were collected ten days after challenge.

VII.A.9. Enzyme-linked Immunosorbent Assay (ELISA) In order to determine the gIV-speciEic antibody responses of the calves, the ELISA was performed essentially as previously described (Van Drunen Littel-van den Hurk (1984) Virology 135:466). Polystyrene microtiter plates (Immulon ~, Dynatech Laboratories Inc., Alexandria, VA, USA) were coated with 0.05 ug purified gIV per well and incubated with serially diluted bovine sera. Affinity-purified horseradish peroxidase (HRPO)-conjugated rabbit anti-bovine IgG (Kirkegaard & Perry Laboratories, ~laithersburg, Maryland, USA), at a dilution 35 of 1:5000, was used as the dete~ting antibody. Antibody RBNS06FO.WP .12 : :. ,: :
;

29310-20005.20 Client ID None PATENT

isotypes were determined in an indirect ELISA using gIV-coated plates and isotype-specific monoclonal antibodies (provided by Dr. K. Nielsen, Agriculture Canada, Animal Diseases Research Institute, Nepean). Affinity-purified HRPO-conjugated goat anti-mouse IgG (Boehringer-Mannheim, Dorval, Quebec, Canada) at a dilution of 1:10,000 was used as the detecting antibody.

VII.A.10. Competitive Antibody Bindinq Assay (CsA) The CBA was based on the ELISA modified as previously described (Van Drunen Littel-van den Hurk et al. (1985) Virology 144:216-227). Briefly, gIV coated plates were incubated with serially diluted competitor antibodies from the gIV-immunized calves. After a 1 hour incubation at 37C, the plates were washed and incubated with HRPO-conjugated monoclonal antibodies specific for eight different epitopes on gIV (Van Drunen Littel-van den Hurk (1984) Virology 135:466; and Hughes et al.
(1988) Arch. Virol. 103:47). After a 3 hour incubation at 37C, the plates were washed again and developed. The percentage competition was calculated using the formula [lOOx(A-~3)/A] where A is absorbance in absence of competitor antibody and ~ is absorbance in the presence of competitor monospecific antibody.
VII.A.11. Neutralization Test The neutralization titers of the bovine sera were determined as described previously (~3abiuk, L.A. et al. (1975) Infect.Immun. 12:958). The titers ~ere expressed as the reciprocal of the highest dilution of antibody that caused a 50~ reduction of plaques relative to the virus control. Neutralization titers were also determined for the nasal swabs of the immunized animals and calculated in the same manner.

RBNSO 6FO . WP . 12 . '. ' ~ ' ; ' ~ ~

29310-20005.20 Client ID None PAI'ENT

VII.B. Results VII.B.l. Purification of Authentic and Recombinant gIV
Authentic and recombinant gIVs were purified on gIV-specific monoclonal antibody columns. All of the recombinant gIV glycoproteins were produced at higher levels than the authentic gIV from BHV-l (Table 2).

Table 2 Source of gIV aYield (ug/106 cells) BHV-l 1 - 2.5 Baculovirus 15 - 35 15 Adenovirus 3.5 - 8.5 Vaccinia virus 2.5 - 5.5 E. coli b500 - 1000 a The yields of gIV from mammalian cells were determined with the BioRad protein determination kit.
_ The yields of gIV from E. coli are expressed in ug per liter and represent values obtained on bench scale before optimalization.

The purity of the glycoprotein preparations was assessed by SDS-PAGE. All of the recombinant forms of gIV bound specifically to the columng. The apparent molecular weights of authentic gIV and gIV from vaccinia virus and adenovirus were identical, indicating that processing and glycosylation of authentic gIV in MDBK cells and recombinant gIV in BSC-l or 293 cells are very similar.
Recombinant gIV from baculovirus, however, had an apparent molecular weight of 63 kDa, which is lo~er than that of the 71 kDa authentic form. In addition to the 63 kDa species, four bands of lower apparent molecular RBNS06FO .WP .12 "`: ; . ~ ` '`

, 29310-20005.20 Client ID None PATENT

weight were observed. These bands were consistently seen both in pure and in crude preparations of gIV from baculovirus. Recombinant gIV from E. coli had an apparent molecular weight of 54 }~a, which corresponds to the molecular weight of the unglycosylated form of gIV
(Van Drunen Littel-van den Hurk (1986) Virol. 59:401-410). As about 50~ of the total protein preparation from E. coli consisted of gIV, this recombinant protein was not further purified. The gIV from E. coli was not dimerized at all, whereas the gIV from baculovirus showed a much reduced degree of dimerization as compared to authentic gIV.

VII.B.2 Immune Res~onses to Authentic and Recombinant gIV
In order to determine whether the different forms of recombinant gIV have the same protective capacity as authentic gIV, they were evaluated in a BHV-1 challenge experiment as described above. The level and the specificity of the total antibody response following immunization was determined in an ELISA using authentic gIV, gI or gIII as the antigens. As shown in Figure 24A, after one immunization, high levels of gIV-specific antibodies were found in the sera of all immunized animals. The antibody titers increased following the booster immunization. There was no significant difference between the antibody titers induced by gIV
from BHV-1, baculovirus, adenovirus or vaccinia virus.
However, the antibody titers generated by gIV from E.
coli were 5-fold higher after the booster immunization.
None of the animals reacted with gI or gIII, showing the specificity of the immune response. In no case did the placebo-vaccinated animals produce any immune response.
In order to predict the effectiveness of the glycoprotein-specific antibodies to prevent infection, RBNS06FO . WP .12 `

: ~

.; , 29310-20005.20 Client ID ~one PATBNT

the serum neutralizing antibody titers were determined.
Figure 2~B indicates that after one immunization, gIV
from BHV-1, baculovirus, adenovirus and vaccinia virus induced reasonably good levels of neutralizing antibodies, which increased to very high levels following the booster immunization. Again, there was essentially no difference between the immune responses to these four forms of gIV. In contrast, there was a significant difference in the neutralizing antibody response to gIV
from E. coli. Even after two immunizations, the neutralizing antibody titer induced by this form of gIV
was lower than the level induced by one immunization of any of the other forms of gIV.
The contribution of antibody isotypes to the immune response was investigated by indirect ELISA
(Figure 25). The IgG1 titers (Figure 25A) were higher than the IgG2 titers (Figure 25B) throughout the period before challenge. The IgG1 titers reached peak values after two immunizations and then started to plateau and decrease after challenge. The IgG2 titers were lower initially, but generally continued to increase after challenge. The IgM titers (Figure 25C) were much lower than the IgG1 or IgG2 titers throughout the duration of the experiment. The antibody isotypes were generally similar between the groups immunized with the different forms of recombinant gIV. However, the IgM levels induced by gIV from E. coli were significantly higher than those induced by the other forms of gIV. The IgG1 response, however, was slower in this group.
VII.B.3. Epitope Specificity of the Immune Response to Authentic and Recombinant gIV
Recombinant gIV from E. coli induced a lower level of neutralizing antibodies to BHV-1 than the other recombinant gIVs, although the total antibody response RB~SO 6FO . WP .12 1:
.: , ` :` `: ; ~ , . . ~ .

29310-20005.20 Client ID None PATENT

was equivalent or higher. In order to determine which of the neutralizing epitopes on gIV were recognized, the sera from all immunized animals ~were tested with respect to epitope specificity. Seven neutralizing epitopes (epitopes Ia, Ib, II, IIIa, IIIb, IIIc, and IIId) and one non-neutralizing epitope (epitope IV) have been mapped on gIV (Hughes et al. (1988) Arch. Virol. 103:47). All epitopes on gIV were recognized by animals immunized with gIV from BHV-1, baculovirus, adenovirus, or vaccinia virus; blocking varied between 30 and g5~, depending on the epitope (Figure 26). These values correlate well with previously reported values between 30 and 85~ (Van Drunen Littel-van den Hurk (1990) Vaccine 8:358-368).
However, the neutralizing epitopes on gIV were either not at all (Ia, Ib, II, IIIa, and IIIb), or poorly (IIIc and IIId) recognized by animals immunized with gIV from E.
coli. The only epitope recognized well by these animals was the non-neutralizing epitope IV. These results indicate that the neutralizing epitopes on gIV, most of which are conformation-dependent (Hughes et al. (1988) Arch. Virol. 103:47), are present on gIV from baculovirus, adenovirus and vaccinia virus, but not on gIV from E. coli.

VII.B.4. Protection from Challenqe with BHV-1 All animals were challenged with an aerosol of BHV-1. Prior to challenge, all animals were healthy and they had a normal rectal temperature. However, wlthin 24 h post infection, the animals in the placebo-immunized group started to exhibit a sharp rise in temperature.
The temperatures continued to increase until three days post challenge, whereafter they declined again. There was no significant increase in temperature in the gIV-vaccinated groups, although the animals immunized with gIV from E. coli did experience some elevated RB~S06FO .WP .12 , `, ;

293:L0-20005.20 Client ID None PATENT
-g8-temperatures during the first two days after infection (Figure 27A). In addition to the temperature responses the calves were clinically evaluated for signs of respiratory disease. The clinical illness scores correlated well with the temperature responses. The animals in the placebo-immunized group showed signs of clinical illness from day 1 until day 7 post challenge, whereas the groups immunized with gIV from BHV-l, baculovirus, adenovirus or vaccinia virus experienced no illness at all. The group that received gIV from E. coli showed mild disease for three days after infection (Figure 27B). A further non-subjective asse~sment of morbidity is the extent of weight loss of animals challenged with BHV-l. The weight 1099 observed in the placebo-immunized group is a reflection of the anorexia as a result of the morbidity due to viral challenge. In contrast to the placebo-immunized group, gIV immunized animals experienced minimal or no weight 109s during the 8 days following challenge (Figure 28).
VII.B.5. Induction of Mucosal Immunity With the exception of the group immunized with gIV from E. coli, all animals vaccinated with authentic or recombinant gIV were fully protected from disease, when challenged with BHV-l. To determine whether they were also protected from viral infection, the extent of virus shedding from the nasal passages was assessed.
Figure 29A demonstrates that essentially no virus was recovered from the nasal swabs of animals vaccinated with gIV from BHV-l, baculovirus, adenovirus or vaccinia virus. One animal in each of the groups vaccinated with gIV from baculovirus and adenovirus shed virus for one day. In contrast, all animals immunized with gIV from E.
coli or placebo shed virus for 7 to 9 days post challenge. These data indicated that intramuscular RE~NS0 6Y0 . WP . 12 , .' , . '. ~' :
~',' : ' , ~ :. ' , , 29310-20005.20 Client ID None PAI'ENT
_99_ immunization with a subunit vaccine induced mucosal immunity in the nasal passages, thereby preventing viral infection. In addition, the extent of the mucosal immunity appeared to correlate with the level of the neutralizing antibodies in the serum. To confirm the presence of a mucosal immune response in the nasal passages, the antibody titers in the nasal swabs were determined. On the challenge day, groups vaccinated with gIV from BHV-l, baculovirus, adenovirus, or vaccinia virus had mean neutralizing antibody titers between 25 and 65 (Figure 29B). The gIV-specific ELISA titers, also shown in Figure 29B, correlated well with the neutralizing antibody titers. The group immunized with gIV from E. coli did not have any neutralizing antibodies in the nasal secretions, although the total gIV-specific antibody levels were as high as in the other groups. No gI-or gIII-specific antibodies were found in the nasal secretions (data not shown). These data correlate well with the serum antibody levels.
DEPOSIT OF BIOLOGICAL MATERIALS
The following materials have been deposited or will be deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, 25 Maryland 20852, U.S.A. during the pendancy of this application. These deposits will be maintained under the terms of the Budapest Treaty on the deposit of microorganisms. The nucleotide sequences of the deposited materials are incorporated by reference herein, as well as the sequences of polypeptides encoded thereby.
In the event of any discrepancy between a sequence expressly disclosed herein and a deposited sequence, the deposited sequence is controlling. The deposit of the sequence is not the grant of a license to make, use or sell any of the deposited materials.

RBNS06FO . WP .12 .
:` ' ;`;' ~
- ~: , 29310-20005.20 Client ID None PATENT

Material Accession Number Deposit Date lEll-lF6 HB 9774 July 22, 1988 lD6-Gll HB 9775 July 22, 1988 lG6-2D9 HB 9776 July 22, 1988 VAC-I VR 2223 July 22, 1988 VAC-III VR 2224 July 22, 1988 RSV-gI CRL 9780 July 22, 1988 RSV-gIII CRL 9779 July 22, 1988 10 SV2gI CRL 9778 July 22, 1988 SV2gIII CRL 9777 July 22, 1988 pVSL-l p W-l/gI
p W-l/gIII
p W-l/gIV
p W-l/gIVt pVLgI
pVLgIII
pVLgIV
pVLgIVt pAdBM5.gIV
pAdBM5.gIVt pgpll complete pBHC150 pBHDsib While the present invention has been illustrated above by certain speciric embodiments, it is not intended that the specific examples should limit the scope of the invention as described in the appended claims.

RBNS06FO . WP .12

Claims (43)

1. A vaccine composition comprising a pharmaceutically acceptable vehicle and at least one recombinant subunit antigen, said at least one recombinant subunit antigen comprising one or more neutralizing epitopes of a bovine herpesvirus type 1 (BHV-1) glycoprotein, said glycoprotein selected from the group consisting of BHV-l gI, BHV-1 gIII and BHV-1 gIV.

2. The vaccine composition of claim 1 wherein said composition comprises one or more neutralizing epitopes of BHV-1 gI.

3. The vaccine composition of claim 1 wherein said composition comprises one or more neutralizing epitopes of BHV-1 gIII.

4. The vaccine composition of claim 1 wherein said composition comprises one or more neutralizing epitopes of BHV-1 gIV.

5. The vaccine composition of claim 1 wherein said composition comprises one or more neutralizing epitopes of BHV-1 gI and one or more neutralizing ::
epitopes of BHV-1 gIII.

6. The vaccine composition of claim 1 wherein said composition comprises one or more neutralizing epitopes of BHV-1 gI and one or more neutralizing epitopes of BHV-1 gIV.

7. The vaccine composition of claim 1 wherein said composition comprises one or more neutralizing RBNS06F2.WP .01 29310-20005.20 Client ID None PATENT

epitopes of BHV-1 gIII and one or more neutralizing epitopes of BHV-1 gIV.

8. The vaccine composition of claim 1 wherein said composition comprises one or more neutralizing epitopes of BHV-1 gI, one or more neutralizing epitopes of BHV-1 gIII and one or more neutralizing epitopes of BHV-1 gIV.

9. The vaccine composition of claim 1 further comprising an adjuvant.

10. A nucleotide sequence encoding a protein substantially homologous and functionally equivalent to BHV-1 gI, or an immunogenic fragment thereof.

11. The nucleotide sequence of claim 10 wherein said sequence comprises a contiguous nucleotide sequence depicted in Figure 5.

12. A nucleotide sequence encoding a protein substantially homologous and functionally equivalent to BHV-1 gIII, or an immunogenic fragment thereof.

13. The nucleotide sequence of claim 12 wherein said sequence comprises a contiguous nucleotide sequence depicted in Figure 6.

14. A nucleotide sequence encoding a protein substantially homologous and functionally equivalent to BHV-1 gIV, or an immunogenic fragment thereof.

15. The nucleotide sequence of claim 14 wherein said sequence comprises a contiguous nucleotide sequence depicted in Figure 7.
RBNS06F2.WP .01 29310-20005.20 Client ID None PATENT

16. A DNA construct comprising an expression cassette comprised of:
(a) a DNA coding sequence for a polypeptide containing at least one neutralizing epitope of a BHV-1 glycoprotein, said BHV-1 glycoprotein selected from the group consisting of gI, gIII and gIV; and (b) control sequences that are operably linked to said coding sequence whereby said coding sequence can be transcribed and translated in a host cell, and at least one of said control sequences is heterologous to said coding sequence.

17. A host cell stably transformed by a DNA
construct according to claim 16.

18. The host cell of claim 17 wherein said host cell is a procaryote.

19. The host cell of claim 18 wherein said procaryote is E. coli.

20. The host cell of claim 17 wherein said host cell is a virus.

21. The host cell of claim 20 wherein said virus is a recombinant vaccinia virus.

22. The host cell of claim 17 wherein said host cell is a eucaryote.

23. The host cell of claim 22 wherein said eucaryote is an insect cell.

RBNS06F2.WP .01 29310-20005.20 Client ID None PATENT

24. The host cell of claim 23 wherein said insect cell is Spodoptera frugiperda.

25. The host cell of claim 22 wherein said eucaryote is a mammalian cell.

26. The host cell of claim 25 wherein said mammalian cell is transformed with a recombinant adenovirus vector.

27. The host cell of claim 25 wherein said mammalian cell is transformed with a recombinant Rous sarcoma virus vector.

28. The host cell of claim 25 wherein said mammalian cell is transformed with a recombinant simian virus vector.

29. A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 17; and (b) growing said population of cells under conditions whereby the polypeptide encoded by said expression cassette is expressed.

30. A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 19; and (b) growing said population of cells under conditions whereby the polypeptide encoded by said expression cassette is expressed.

RBNS06F2.WP . 01 29310-20005.20 Client ID None PATENT

31. A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 21; and (b) growing said population of cells under conditions whereby the polypeptide encoded by said expression cassette is expressed.

32. A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 24; and (b) growing said population of cells under conditions whereby the polypeptide encoded by said expression cassette is expressed.

33. A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 26; and (b) growing said population of cells under conditions whereby the polypeptide encoded by said expression cassette is expressed.

34. A method of producing a recombinant polypeptide comprising:
(a) providing a population of host cells according to claim 27; and (b) growing said population of cells under conditions whereby the polypeptide encoded by said expression cassette is expressed.

35. A method of producing a recombinant polypeptide comprising:

RBNS06F2.WP .01 29310-20005.20 Client ID None PATENT

(a) providing a population of host cells according to claim 28; and (b) growing said population of cells under conditions whereby the polypeptide encoded by said expression cassette is expressed.

36. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 1.

37. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 2.

38. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 3.

39. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 4.

40. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 5.

41. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 6.
RBNS06F2.WP .01 29310-20005.20 Client ID None PATENT

42. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 7.

43. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 8.

RBNS06F2.WP .01